



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07H 21/04, C07K 14/00, C12N 1/21, 5/10, 15/12, C12P 21/00, C12Q 1/68, G01N 33/53</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/31701</b>  <b>(43) International Publication Date:</b> 23 July 1998 (23.07.98)
<b>(21) International Application Number:</b> PCT/US98/00813 <b>(22) International Filing Date:</b> 16 January 1998 (16.01.98) <b>(30) Priority Data:</b> 08/785,241                      17 January 1997 (17.01.97)                      US <b>(71) Applicant:</b> BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US). <b>(72) Inventors:</b> MCKNIGHT, Steven, L.; U.T. Southwestern Medical Center, Dept. of Biochemistry, 5323 Harry Hines Boulevard, Dallas, TX 75235-9152 (US). RUSSEL, David, W.; U.T. Southwestern Medical Center, Dept. of Biochemistry, 5323 Harry Hines Boulevard, Dallas, TX 75235-9152 (US). TIAN, Hui; U.T. Southwestern Medical Center, Dept. of Biochemistry, 5323 Harry Hines Boulevard, Dallas, TX 75235-9152 (US). <b>(74) Agent:</b> OSMAN, Richard, Aron; Science & Technology Law Group, 75 Denise Drive, Hillsborough, CA 94010 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> ENDOTHELIAL PAS DOMAIN PROTEIN <b>(57) Abstract</b> <p>The invention provides methods and compositions relating to endothelial PAS domain protein 1 (EPAS1) and related nucleic acids. The proteins may be produced recombinantly from transformed host cells from the disclosed EPAS1 encoding nucleic acids or purified from human cells. The invention provides isolated EPAS1 hybridization probes and primers capable of specifically hybridizing with the disclosed EPAS1 gene, EPAS1-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## ENDOTHELIAL PAS DOMAIN PROTEIN

The research carried out in the subject application was supported in part by grants  
5 from the National Institutes of Health. The government may have rights in any patent issuing  
on this application.

## INTRODUCTION

Field of the Invention

10 The field of this invention is transcription factor proteins involved in vascularization.

Background

Roughly a dozen proteins classified as basic helix-loop-helix/PAS domain  
transcription factors have been described in both vertebrates and invertebrates. Members of  
15 this class derive their name from the shared presence of a basic helix-loop-helix (bHLH)  
motif that specifies sequence dependent recognition of DNA and a PAS domain composed of  
two imperfect repeats. PAS is an acronym derived from the first three proteins observed to  
contain this motif. These include the product of the *period* gene of *Drosophila melanogaster*  
(Jackson et al. 1986; Citri et al. 1987), the aryl hydrocarbon nuclear transporter gene (ARNT)  
20 of mammals (Burbach et al. 1992), and the product of the fruit fly *single-minded* gene  
(Nambu et al. 1991).

The imperfect, direct repeats within the PAS domain are approximately 50 amino  
acids in length and contain a signature His-X-X-Asp sequence in each repeat. Three  
biochemical functions have been assigned to the PAS domain. First, it acts in concert with  
25 the helix-loop-helix domain of bHLH/PAS proteins to form a dimerization surface (Reisz-  
Porszasz et al. 1994; Fukunaga et al. 1995; Lindebro et al. 1995). In the case of the *period*  
gene product, which lacks a bHLH domain, the PAS domain specifies heterodimerization  
with the product of the *timeless* locus (Gekakis et al. 1995; Myers et al. 1995). Interaction  
between the *period* and *timeless* gene products represents a crucial event in the control of  
30 circadian rhythm in fruit flies (Hunter-Ensor et al. 1996; Lee et al. 1996; Myers et al. 1996;  
Zeng et al 1996). In contrast, the aryl hydrocarbon receptor (AHR) heterodimerizes with

ARNT via PAS domain interactions (Fukunaga et al. 1995), producing a heterodimer that is competent for nuclear gene interaction. Second, the PAS domain mediates interaction with heat shock protein 90 (HSP-90). Several PAS domain proteins, including the *single-minded* gene product and the AHR, can be sequestered in the cytoplasm in an inactive state. Maintenance of the inactive state involves interactions between the PAS domain and HSP-90 (Perdew, 1988; Chen and Perdew, 1994; Henry and Gasiewicz, 1993; McGuire et al. 1995). Finally, the PAS domain of the AHR facilitates high affinity binding of certain xenobiotic compounds including dioxin (reviewed in Hankinson, 1995; Schmidt and Bradfield, 1996).

PAS domain transcription factors perform diverse functions in a variety of cell types and organisms. The *period* gene product helps regulate circadian rhythm in fruit flies (Konopka and Benzer, 1971), whereas the mammalian AHR provides response to xenobiotics by activating genes whose products facilitate detoxification (Schmidt and Bradfield, 1996). A more recently described member of the PAS domain family, hypoxia inducible factor (HIF-1 $\alpha$ ), activates genes whose products regulate hematopoiesis in response to oxygen deprivation (Wang et al. 1995). In *Drosophila*, the *single-minded* gene product affects neurogenesis (Nambu et al. 1991) and the *trachealess* gene product controls the formation of tubular structures in the embryo (Wilk et al. 1996; Isaac and Andrew, 1996).

The utilization of bHLH/PAS domain proteins in diverse species and physiological processes raises the possibility that this family of transcription factors might consist of many undiscovered members. Here we report the initial characterization of new members of this protein family collectively designated endothelial PAS domain protein 1 (EPAS1).

## SUMMARY OF THE INVENTION

The invention provides methods and compositions relating to endothelial PAS domain protein 1 (EPAS1), related nucleic acids, and protein domains thereof having EPAS1-specific activity. EPAS1 proteins can regulate specification of endothelial tissue, such as vasculature, the blood brain barrier, etc. The proteins may be produced recombinantly from transformed host cells from the subject EPAS1 encoding nucleic acids or purified from mammalian cells. The invention provides isolated EPAS1 hybridization probes and primers capable of specifically hybridizing with the disclosed EPAS1 gene, EPAS1-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis (e.g. genetic hybridization screens for EPAS1 transcripts), therapy (e.g. gene

therapy to modulate EPAS1 gene expression) and in the biopharmaceutical industry (e.g. as immunogens, reagents for isolating B-cell specific activators or other transcriptional regulators, reagents for screening chemical libraries for lead pharmacological agents, etc.).

#### SEQ ID NO: LISTING

- 5 SEQ ID NO:1: human EPAS1 cDNA.  
SEQ ID NO:2: murine EPAS1 cDNA.  
SEQ ID NO:3: HIF-1 $\alpha$  binding site.  
SEQ ID NO:4: human EPAS1 protein.  
SEQ ID NO:5: murine EPAS1 protein.  
10 SEQ ID NO:6: human HIF-1 $\alpha$ protein.  
SEQ ID NO:7: murine HIF-1 $\alpha$  protein

#### DETAILED DESCRIPTION OF THE INVENTION

The nucleotide sequence of a natural cDNA encoding a human and murine EPAS1  
15 proteins are shown as SEQ ID NOS:1 and 2, respectively, and the full conceptual translates as  
SEQ ID NOS:4 and 5, respectively. The EPAS1 proteins of the invention include incomplete  
translates of SEQ ID NOS:1 and 2 and deletion mutants of SEQ ID NOS:4 and 5, which  
translates and deletion mutants have EPAS1-specific amino acid sequence and binding  
specificity or function. Such active EPAS1 deletion mutants, EPAS1 peptides or protein  
20 domains comprise at least 14, preferably at least about 16, more preferably at least about 20  
consecutive residues of SEQ ID NO:4 or 5. For examples, EPAS1 protein domains identified  
below are shown to provide dimerization, protein-binding, and nucleic acid binding function.  
Additional such domains are identified in and find use, *inter alia*, in solid-phase binding  
assays as described below.

25 EPAS1-specific activity or function may be determined by convenient *in vitro*, cell-  
based, or *in vivo* assays: e.g. *in vitro* binding assays, cell culture assays, in animals (e.g.  
immune response, gene therapy, transgenics, etc.), etc. Binding assays encompass any assay  
where the molecular interaction of an EPAS1 protein with a binding target is evaluated. The  
binding target may be a natural intracellular binding target such as another bHLH/PAS  
30 protein, a heat shock protein, or a nucleic acid sequence/binding site or other regulator that  
directly modulates EPAS1 activity or its localization; or non-natural binding target such a

specific immune protein such as an antibody, or an EPAS1 specific agent such as those identified in screening assays such as described below. EPAS1-binding specificity may assayed by binding equilibrium constants (usually at least about  $10^7 \text{ M}^{-1}$ , preferably at least about  $10^8 \text{ M}^{-1}$ , more preferably at least about  $10^9 \text{ M}^{-1}$ ), by the ability of the subject protein to function as negative mutants in EPAS1-expressing cells, to elicit EPAS1 specific antibody in a heterologous host (e.g a rodent or rabbit), etc. In any event, the EPAS1 binding specificity of the subject EPAS1 proteins necessarily distinguishes HIF-1 $\alpha$ .

The claimed EPAS1 proteins are isolated or pure: an "isolated" protein is unaccompanied by at least some of the material with which it is associated in its natural state, preferably constituting at least about 0.5%, and more preferably at least about 5% by weight of the total protein in a given sample and a pure protein constitutes at least about 90%, and preferably at least about 99% by weight of the total protein in a given sample. The EPAS1 proteins and protein domains may be synthesized, produced by recombinant technology, or purified from mammalian, preferably human cells. A wide variety of molecular and biochemical methods are available for biochemical synthesis, molecular expression and purification of the subject compositions, see e.g. Molecular Cloning, A Laboratory Manual (Sambrook, *et al.* Cold Spring Harbor Laboratory), Current Protocols in Molecular Biology (Eds. Ausubel, *et al.*, Greene Publ. Assoc., Wiley-Interscience, NY) or that are otherwise known in the art.

The invention provides natural and non-natural EPAS1-specific binding agents, methods of identifying and making such agents, and their use in diagnosis, therapy and pharmaceutical development. For example, EPAS1-specific agents are useful in a variety of diagnostic and therapeutic applications. Novel EPAS1-specific binding agents include EPAS1-specific receptors, such as somatically recombined protein receptors like specific antibodies or T-cell antigen receptors (see, e.g Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory) and other natural intracellular binding agents identified with assays such as one-, two- and three-hybrid screens, non-natural intracellular binding agents identified in screens of chemical libraries such as described below, etc. For diagnostic uses, the binding agents are frequently labeled, such as with fluorescent, radioactive, chemiluminescent, or other easily detectable molecules, either conjugated directly to the binding agent or conjugated to a probe specific for the binding agent. Agents of particular interest modulate EPAS1 function, e.g. EPAS1-dependent

transcriptional activation; for example, isolated cells, whole tissues, or individuals may be treated with an EPAS1 binding agent to activate, inhibit, or alter EPAS1-dependent transcriptional processes.

The amino acid sequences of the disclosed EPAS1 proteins are used to back-translate EPAS1 protein-encoding nucleic acids optimized for selected expression systems (Holler et al. (1993) Gene 136, 323-328; Martin et al. (1995) Gene 154, 150-166) or used to generate degenerate oligonucleotide primers and probes for use in the isolation of natural EPAS1-encoding nucleic acid sequences ("GCG" software, Genetics Computer Group, Inc, Madison WI). EPAS1-encoding nucleic acids used in EPAS1-expression vectors and incorporated into recombinant host cells, e.g. for expression and screening, transgenic animals, e.g. for functional studies such as the efficacy of candidate drugs for disease associated with EPAS1-modulated transcription, etc.

The invention also provides nucleic acid hybridization probes and replication / amplification primers having a EPAS1 cDNA specific sequence contained in SEQ ID NO:1 and sufficient to effect specific hybridization thereto (i.e. specifically hybridize with SEQ ID NO:1 in the presence of endothelial cell cDNA). Such primers or probes are at least 12, preferably at least 24, more preferably at least 36 and most preferably at least 96 bases in length. Demonstrating specific hybridization generally requires stringent conditions, for example, hybridizing in a buffer comprising 30% formamide in 5 x SSPE (0.18 M NaCl, 0.01 M NaPO<sub>4</sub>, pH7.7, 0.001 M EDTA) buffer at a temperature of 42°C and remaining bound when subject to washing at 42°C with 0.2 x SSPE; preferably hybridizing in a buffer comprising 50% formamide in 5 x SSPE buffer at a temperature of 42°C and remaining bound when subject to washing at 42°C with 0.2 x SSPE buffer at 42°C. EPAS1 cDNA homologs can also be distinguished from other protein using alignment algorithms, such as BLASTX (Altschul *et al.* (1990) Basic Local Alignment Search Tool, J Mol Biol 215, 403-410).

The subject nucleic acids are of synthetic/non-natural sequences and/or are isolated, i.e. unaccompanied by at least some of the material with which it is associated in its natural state, preferably constituting at least about 0.5%, preferably at least about 5% by weight of total nucleic acid present in a given fraction, and usually recombinant, meaning they comprise a non-natural sequence or a natural sequence joined to nucleotide(s) other than that which it is joined to on a natural chromosome. Nucleic acids comprising the nucleotide sequence of

SEQ ID NO:1 or 2 or fragments thereof, contain such sequence or fragment at a terminus, immediately flanked by a sequence other than that which it is joined to on a natural chromosome, or flanked by a native flanking region fewer than 10 kb, preferably fewer than 2 kb, which is at a terminus or is immediately flanked by a sequence other than that which it is joined to on a natural chromosome. While the nucleic acids are usually RNA or DNA, it is often advantageous to use nucleic acids comprising other bases or nucleotide analogs to provide modified stability, etc.

The subject nucleic acids find a wide variety of applications including use as translatable transcripts, hybridization probes, PCR primers, diagnostic nucleic acids, etc.; use in detecting the presence of EPAS1 genes and gene transcripts and in detecting or amplifying nucleic acids encoding additional EPAS1 homologs and structural analogs. In diagnosis, EPAS1 hybridization probes find use in identifying wild-type and mutant EPAS1 alleles in clinical and laboratory samples. Mutant alleles are used to generate allele-specific oligonucleotide (ASO) probes for high-throughput clinical diagnoses. In therapy, therapeutic EPAS1 nucleic acids are used to modulate cellular expression or intracellular concentration or availability of active EPAS1.

The invention provides efficient methods of identifying agents, compounds or lead compounds for agents active at the level of a EPAS1 modulatable cellular function. Generally, these screening methods involve assaying for compounds which modulate EPAS1 interaction with a natural EPAS1 binding target. A wide variety of assays for binding agents are provided including labeled *in vitro* protein-protein binding assays, immunoassays, cell based assays, etc. The methods are amenable to automated, cost-effective high throughput screening of chemical libraries for lead compounds. Identified reagents find use in the pharmaceutical industries for animal and human trials; for example, the reagents may be derivatized and rescreened in *in vitro* and *in vivo* assays to optimize activity and minimize toxicity for pharmaceutical development. Target indications include neoproliferative disease, inflammation, hypersensitivity, wound healing, immune deficiencies, infection etc.

*In vitro* binding assays employ a mixture of components including an EPAS1 protein, which may be part of a fusion product with another peptide or polypeptide, e.g. a tag for detection or anchoring, etc. The assay mixtures comprise a natural intracellular EPAS1 binding target. While native binding targets may be used, it is frequently preferred to use portions (e.g. peptides) thereof so long as the portion provides binding affinity and avidity to



the subject EPAS1 protein conveniently measurable in the assay. The assay mixture also comprises a candidate pharmacological agent. Candidate agents encompass numerous chemical classes, though typically they are organic compounds; preferably small organic compounds and are obtained from a wide variety of sources including libraries of synthetic or natural compounds. A variety of other reagents may also be included in the mixture. These include reagents like salts, buffers, neutral proteins, e.g. albumin, detergents, protease inhibitors, nuclease inhibitors, antimicrobial agents, etc. may be used.

The resultant mixture is incubated under conditions whereby, but for the presence of the candidate pharmacological agent, the EPAS1 protein specifically binds the cellular binding target, portion or analog with a reference binding affinity. The mixture components can be added in any order that provides for the requisite bindings and incubations may be performed at any temperature which facilitates optimal binding. Incubation periods are likewise selected for optimal binding but also minimized to facilitate rapid, high-throughput screening.

After incubation, the agent-biased binding between the EPAS1 protein and one or more binding targets is detected by any convenient way. For cell-free binding type assays, a separation step is often used to separate bound from unbound components. Separation may be effected by precipitation (e.g. TCA precipitation, immunoprecipitation, etc.), immobilization (e.g. on a solid substrate), etc., followed by washing by, for examples, membrane filtration (e.g. Whatman's P-81 ion exchange paper, Polyfiltronic's hydrophobic GFC membrane, etc.), gel chromatography (e.g. gel filtration, affinity, etc.). For EPAS1-dependent transcription assays, binding is detected by a change in the expression of an EPAS1-dependent reporter.

Detection may be effected in any convenient way. For cell-free binding assays, one of the components usually comprises or is coupled to a label. The label may provide for direct detection as radioactivity, luminescence, optical or electron density, etc. or indirect detection such as an epitope tag, an enzyme, etc. A variety of methods may be used to detect the label depending on the nature of the label and other assay components, e.g. through optical or electron density, radiative emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, etc.

A difference in the binding affinity of the EPAS1 protein to the target in the absence of the agent as compared with the binding affinity in the presence of the agent indicates that

the agent modulates the binding of the EPAS1 protein to the EPAS1 binding target. Analogously, in the cell-based transcription assay also described below, a difference in the EPAS1 transcriptional induction in the presence and absence of an agent indicates the agent modulates EPAS1-induced transcription. A difference, as used herein, is statistically significant and preferably represents at least a 50%, more preferably at least a 90% difference.

5           The following experimental section and examples are offered by way of illustration and not by way of limitation.

### EXPERIMENTAL

cDNAs encompassing the coding region of the human EPAS1 were isolated by screening a HeLa cell cDNA library with a radiolabeled probe derived from an expressed sequence tag (#T70415) obtained from the Genbank data base (see Materials and Methods). Multiple cDNA clones were isolated and subjected to DNA sequence analysis to derive the conceptually translated protein sequence of human EPAS1 shown in Table 1. The predicted  $M_r$  of the human EPAS1 was 96,528. A termination codon was located 24 nucleotides 5' of the designated initiator methionine in the human sequence. cDNAs encoding the murine homologue were isolated from an adult mouse brain cDNA library using a probe obtained by reverse transcriptase polymerase chain reactions with oligonucleotide primers derived from the human EPAS1 cDNA sequence (see Materials and Methods). The predicted protein sequence of murine EPAS1 is aligned and compared with the human sequence in Table 1. The two proteins share 88% sequence identity. Data base searches revealed that the human and murine EPAS1 proteins share extensive primary amino acid sequence identity with hypoxia inducible factor-1 $\alpha$  (HIF-1 $\alpha$ ), a member of the bHLH/PAS domain family of transcription factors (Wang et al. 1995; Wenger et al. 1995). EPAS1 and HIF-1 $\alpha$  share 48% primary amino acid sequence identity as revealed by the alignment shown in Table 1. Sequence conservation between the two proteins is highest in the basic-helix-loop-helix (85%), PAS A (68%) and PAS-B (73%) regions. A second region of sequence identity occurs at the extreme carboxy terminis of the EPAS1 and HIF-1 $\alpha$  proteins. This conserved region in mHIF1 $\alpha$  has been recently shown to contain a hypoxia response domain (Li et al., 1996). EPAS1 also shares sequence relatedness with other PAS domain proteins, however the degree of similarity between EPAS1 and other family members is less striking than that between HIF-1 $\alpha$  and EPAS1.

30           Genomic clones encoding the human EPAS1 transcript were isolated by screening bacteriophage libraries of human DNA. The intron-exon structure of the gene was established

by comparison of DNA sequences obtained from the genomic DNA to that of the cDNA. The coding region of EPAS1 is specified by 15 exons. The exonic sequences mapped to six non-overlapping bacteriophage lambda clones whose average insert size was 20 kb, indicating that the EPAS1 gene spans at least 120 kb of genomic DNA. A comparison of the EPAS1 gene structure with that of the aryl hydrocarbon receptor (Schmidt et al. 1993) reveals that the positions of introns within the regions encoding the amino-terminal halves of the two proteins are highly conserved. In contrast, the portion of the EPAS1 gene specifying the carboxy-terminal half of the protein is interrupted by seven introns, whereas the AHR gene contains only a single intron in this region. Thus the 5'-ends of the two genes may have arisen from an ancient gene duplication event, whereas the 3'-regions have a more recent evolutionary origin.

Two methods were used to determine the chromosomal location of the human EPAS1 gene. Fluorescent in situ hybridization (FISH) analysis was performed using a biotinylated probe containing exons 8-14 of the EPAS1 gene. This analysis revealed a single hybridization signal over chromosome 2, bands p16-p21. As a second assay for gene localization, an oligonucleotide primer pair derived from exon 8 was used to amplify a segment of the EPAS1 gene from the genomic DNAs of a radiation hybrid panel. Computer-assisted analysis of the results indicated linkage of the EPAS1 gene to the D2S288 marker on chromosome 2p with a LOD score of 8.7 and a cR8000 value of 12.96. Thus, the data obtained from two independent mapping methods consistently positioned the EPAS1 gene on the short arm of chromosome 2 and indicate that the EPAS1 gene is non-syntenic with the HIF-1 $\alpha$  gene, which maps to chromosome 14q21-24 (Semenza et al. 1996).

The high degree of sequence similarity between the EPAS1 and HIF-1 $\alpha$  proteins raises the possibility that they share a common physiological function. To test this hypothesis, RNA blotting experiments were used to compare and contrast the distributions of EPAS1 and HIF-1 $\alpha$  mRNAs in a variety of human tissues. An EPAS1 mRNA of approximately 5.8 kb was detected in all tissues examined with the single exception of peripheral blood leukocytes. Among the positive tissues, highly vascularized organs such as the heart, placenta and lung showed the highest levels of EPAS1 mRNA. A HIF-1 $\alpha$  mRNA of approximately 4.4 kb was detected in all human tissues. In contrast to EPAS1 mRNA, however, peripheral blood leukocytes contained very high levels of HIF-1 $\alpha$  mRNA. Likewise, we observed no enrichment of HIF-1 $\alpha$  mRNA in highly vascularized tissues.

These RNA blotting data indicate that, with few exceptions, most tissues express both

EPAS1 and HIF-1 $\alpha$  mRNAs. To determine if this overlap extended to the cellular level, *in situ* mRNA hybridization was used to determine the cell type specific expression patterns of the two gene products. Sections from day 11 and day 13 mouse embryos were examined first. In day 11 embryo sections, EPAS1 transcripts were observed almost exclusively in endothelial cells of the intersegmental blood vessels separating the somites, the atrial and ventricular chambers of the heart, and the dorsal aorta. Extra-embryonic membranes, such as the yolk sac, which are highly vascularized, also expressed abundant levels of EPAS1 mRNA. In the developing brain of a day 13 embryo, endothelial cells of the highly vascularized choroid plexus contained abundant EPAS1 transcripts. The brain section also revealed intense EPAS1 mRNA hybridization in the endothelial cells of a blood vessel lying along the edge of post-mitotic neurons emanating from the lateral ventricle region. When a nearby section was hybridized with an anti-sense probe that was specific for the HIF-1 $\alpha$  mRNA, only a diffuse signal somewhat over background was detected, indicating a low level of HIF-1 $\alpha$  expression in many cell types. In contrast to the results with the EPAS1 probe, no concentration of HIF-1 $\alpha$  mRNA was detected in the endothelial cells of the adjacent blood vessel. A differential expression pattern between EPAS1 and HIF-1 $\alpha$  was also apparent in the region of the embryo containing the umbilicus. EPAS1 transcripts were detected in the endothelium of blood vessels within this structure, whereas HIF-1 $\alpha$  mRNA was concentrated in the mesenchyme surrounding the vascular endothelium.

In tissues of adult mice, EPAS1 mRNA was also detected at high levels in endothelial cells, yet was also present at lower levels in several additional cells types. For example, decidual cells of the placenta contained very high levels of EPAS1 mRNA as did parenchymal tissue in the lung. The distinction between EPAS1 expressing cell types and HIF-1 $\alpha$  expressing cells was also apparent in adult tissues. A section through the cortex of the kidney showed EPAS1 expression in the mesangial cells. In contrast, HIF-1 $\alpha$  expression was found in the cells of the collecting ducts. Taken together, these *in situ* mRNA hybridization results reveal very divergent patterns of EPAS1 and HIF-1 $\alpha$  mRNA distribution.

The presence of basic helix-loop-helix and PAS domain motifs in EPAS1 raised the possibility that this protein might be capable of forming a complex with the aryl hydrocarbon receptor nuclear transport protein (ARNT) (Hoffman et al. 1991), and that the resulting heterodimer might exhibit sequence-specific DNA binding. To test these predictions, EPAS1 and ARNT expression vectors were used to program a reticulocyte lysate. The EPAS1 expression

vector was modified at its carboxy-terminus with a c-Myc epitope tag to facilitate immunological detection of the EPAS1 translation product. Radiolabeled methionine was included in the translation mix containing the ARNT mRNA, whereas unlabeled methionine was used in the EPAS1 reaction. After translation, the two reactions were mixed and subsequently incubated with a monoclonal antibody that recognizes the c-Myc epitope present on the EPAS1 protein. Under these conditions the c-Myc antibody was capable of immunoprecipitating the radiolabeled ARNT protein only when EPAS1-Myc protein was present in the reaction.

The bHLH domains of HIF-1 $\alpha$  and EPAS1 are nearly identical in primary amino acid sequence. Thus, to test for the ability of EPAS1 to form a functional heterodimer with ARNT, we used a HIF-1 $\alpha$  response element derived from the 3'-flanking region of the erythropoietin gene (Semenza and Wang, 1992) in gel mobility shift assays with *in vitro* translated proteins. The data showed that a new complex was formed when both EPAS1 and ARNT were included in the DNA binding reaction, and that this complex was specifically recognized by an anti-peptide antibody directed against the EPAS1 protein. Competition experiments using a 100-fold excess of unlabeled competitor DNA containing the HIF-1 $\alpha$  response element, or a response element with three point mutations in this sequence, indicated that EPAS1 exhibited sequence-specific binding properties. Taken together, the data indicate that EPAS1 is capable of binding the HIF-1 $\alpha$  response element in the presence of the ARNT protein.

The ability of EPAS1 to trans-activate a reporter gene containing the HIF-1 $\alpha$  response element was tested by transient transfection. Expression vectors in which either EPAS1, HIF-1 $\alpha$ , or ARNT were placed under the control of a cytomegalovirus promoter were constructed. Two luciferase reporter constructs were prepared. One contained nucleotides -105 through +58 of the herpes simplex virus thymidine kinase promoter (McKnight et al. 1981) linked to three copies of the HIF-1 $\alpha$  response element from the erythropoietin gene (pRE-tk-LUC). The other contained a TATA sequence from the adenovirus major late gene promoter (Lillie and Green, 1989) linked to the same three HIF-1 $\alpha$  response elements (pE1B-LUC). Combinations of these plasmids were then transfected into cultured human embryonic kidney 293 cells and the expression of luciferase enzyme activity was monitored in cell lysates 16-20 hours post-transfection. The data showed that EPAS1 induced a 12-fold increase in luciferase enzyme activity when transfected in the absence of the ARNT vector. Cotransfection of the ARNT expression vector with low levels of EPAS1 expression vector did not increase the EPAS1-mediated induction of luciferase activity, suggesting that this cell line might contain

adequate amounts of endogenous ARNT to support heterodimer formation with EPAS1. A seven-fold stimulation of luciferase activity was also obtained when larger amounts of the HIF-1 $\alpha$  expression plasmid were introduced into 293 cells. The introduction of three point mutations into the core sequence of the hypoxia response element eliminated both EPAS1-dependent and HIF-1 $\alpha$ -dependent activation of the reporter gene.

5           The potential of HIF-1 $\alpha$  to induce expression of target genes is increased by both hypoxia and pharmacological compounds that mimic hypoxia in cells, such as desferrioxamine (DFX) and cobalt chloride (CoCl<sub>2</sub>) (Wang et al. 1995). To determine if EPAS1 activity might also be stimulated by these agents, 293 cells were incubated under hypoxic conditions or treated with DFX or CoCl<sub>2</sub> prior to transfection with the plasmids. Pretreatment of cells under conditions that  
10       mimic hypoxia increased expression from the luciferase construct in the absence of exogenous EPAS1 or HIF-1 $\alpha$ . This trans-activation presumably arises from endogenous HIF-1 $\alpha$  or EPAS1 proteins whose mRNAs are present in 293 cells. As noted above, introduction of the EPAS1 expression vector led to 5- to 10 times higher levels of luciferase activity over those seen in mock-transfected cells. An extra 2 to 4-fold stimulation of luciferase expression was observed  
15       upon pretreatment with CoCl<sub>2</sub>, DF, or hypoxia relative to that measured in EPAS1- transfected but untreated cells. Of the three conditions, pretreatment with CoCl<sub>2</sub> led to a slightly larger increase in EPAS1 activity, resulting in a four-fold higher level of luciferase activity over that detected in untreated cells. As has been observed in previous studies (Jiang et al. 1996; Forsythe et al. 1996), hypoxic conditions also stimulated the ability of HIF-1 $\alpha$  to trans-activate the target  
20       gene containing the hypoxia response element.

          The EPAS1 expression vector was also tested for its ability to activate a reporter gene (pRE-E1b-LUC) following transfection into murine hepatoma cells (Hepalclc7) that express ARNT, as well as in a mutant line derived from these parental cells that does not express ARNT (c4 variant, Legraverend et al. 1982). Expression of EPAS1 in the Hepalclc7 cells led to a  
25       nine-fold increase in luciferase activity. Transfection of EPAS1 alone into c4 cells increased luciferase enzyme activity only slightly (1.8-fold) whereas cotransfection of EPAS1 and ARNT led to a 12-fold stimulation of activity. These findings are consistent with the interpretation that EPAS1 forms an active heterodimeric transcription factor with ARNT, and they confirm the results showing heterodimerization of these two proteins obtained in coimmunoprecipitation and  
30       gel mobility shift assays.

          The experiments demonstrating the functional activity of EPAS1 utilized a hypoxia

response element derived from the erythropoietin gene, which is a known target gene for HIF-1 $\alpha$  (Semenza and Wang, 1992). Despite the activity of EPAS1 in these assays, as well as the high degree of sequence similarity between HIF-1 $\alpha$  and EPAS1, the in situ mRNA hybridization results indicate that the two proteins are expressed in different cell types and thus might activate different target genes. The high level of expression of EPAS1 in endothelial cells raises the possibility that the EPAS1 protein might activate genes whose expression is limited to endothelial cells. To test this hypothesis, we transfected 293 cells with a c-Myc-tagged EPAS1 expression vector and a marker gene composed of the 5'-flanking region of the *Tie-2* gene linked to  $\beta$ -galactosidase. *Tie-2* encodes a tyrosine kinase receptor that is specifically expressed in cells of endothelial lineage (Dumont et al. 1992; Maison-Pierre et al. 1993; Sato et al. 1993; Schnurch and Risau, 1993). The data showed that EPAS1 potently stimulated expression of the *Tie-2*-driven reporter gene, and that the degree of stimulation correlated with the level of immunodetectable EPAS1 in the transfected cells. Surprisingly, little or no transcriptional activation of the *Tie-2* reporter gene by HIF-1 $\alpha$  was detected, even though equivalent amounts of HIF-1 $\alpha$  and EPAS1 proteins were expressed in the 293 cells.

These data reveal that EPAS1 proteins and nucleic acids provide reagents to modulate the formation of the endothelial tissues including vasculature, the blood brain barrier, etc. and to modulate cellular or tissue responsiveness to oxygenation, hypoxia and other hemodynamic stimuli.

*cDNA and genomic cloning, chromosomal mapping*

In the course of screening for genes that are differentially expressed in prostate adenocarcinoma versus normal tissue, a cDNA encoding a bHLH/PAS domain protein was isolated. Data base searches generated several expressed-sequence tags that showed sequence similarity to this family of transcription factors. EPAS1 cDNAs correspond to the human expressed sequence tag #T70415 in the Genbank collection and were isolated by a combination of reverse transcriptase polymerase chain reactions and screening of a HeLa cell cDNA library (Yokoyama et al. 1993) using standard methods. Similar approaches were used to isolate the murine homologue from a commercially available mouse adult brain cDNA library (#837314, Stratagene Corp., La Jolla, CA). A human HIF-1 $\alpha$  cDNA was generated by ligation of an amplified cDNA fragment to expressed sequence tag hbc025 (Takeda et al. 1993). Bacteriophage  $\lambda$  clones harboring genomic DNA inserts corresponding to the human EPAS1 gene were isolated by screening a commercially available fibroblast genomic library ( $\lambda$ FIXII vector, #946204,

Stratagene Corp.)

Fluorescence in situ hybridization to identify the chromosomal localization of the human EPAS1 gene was carried out as previously described (Craig and Bickmore, 1994). This analysis indicated hybridization to the short arm of chromosome 2, bands p16-21. To confirm the assignment, a 269 bp segment of exon 8 from the EPAS1 gene was amplified from the 83 genomic DNAs of a radiation hybrid panel (Stanford G3 panel, Research Genetics, Huntsville, AL) using oligonucleotide primers and a thermocycler program consisting of 35 cycles of 94°C/1 min, 68°C/1 min. Analysis of the results via an e-mail server at Stanford University indicated linkage to the D2S288 marker (logarithm of the odds score of 8.7, cR\_8000 value of 12.96), which is located approximately 82 centimorgans from the telomere of the short arm of chromosome 2 (MIT Center for Genome Research).

#### *RNA blotting and in situ hybridization*

Human multiple tissue RNA blots (Clontech Laboratories, Palo Alto, CA) were probed with EPAS1 and HIF-1 $\alpha$  cDNA probes using Rapid-Hyb from Amersham Corp. (Arlington Heights, IL). For in situ mRNA hybridization, mouse tissues were fixed in 4% paraformaldehyde, sectioned at 5  $\mu$ m thickness, and subjected to *in situ* mRNA hybridization as described (Berman et al. 1995). A [<sup>32</sup>P]-labeled antisense RNA probe recognizing the EPAS1 mRNA was derived by in vitro transcription of an ~300 bp DNA fragment encoding amino acids 225-327 of the sequence shown in Table 1. A segment of the murine HIF-1 $\alpha$  cDNA encoding amino acids 41-125 was isolated by reverse transcriptase-polymerase chain reactions using mRNA template isolated from embryonic day 10 mouse embryo.

#### *Co-immunoprecipitation experiments*

Human EPAS1 and mouse ARNT proteins were generated in vitro using a transcription-translation kit (TNT System, Promega Corp., Madison, WI). cDNAs encoding full-length proteins were subcloned into the pcDNA3 vector (Invitrogen Corp., San Diego, CA) prior to coupled transcription/translation. For immunoprecipitation, approximately 5  $\mu$ l of each reaction were transferred to a separate tube, mixed well and subsequently diluted by the addition of 500  $\mu$ l of ice-cold buffer (20 mM Hepes-KOH, pH 7.4/ 100 mM KCl/ 10% (v/v) glycerol/ 0.4% (v/v) Nonidet P-40/ 5 mM EGTA/ 5 mM EDTA/ 100  $\mu$ g/ml bovine serum albumin/ 1 mM dithiothreitol) (Huang et al. 1993). The diluted mixture was incubated with 1  $\mu$ l (0.1  $\mu$ g) of anti-Myc monoclonal antibody 9E10 (Santa Cruz Biotechnology, Santa Cruz, CA) for 2 hours at 4°C. A 10  $\mu$ l aliquot of beads (~4 x 10<sup>6</sup> in number, Dynal Corp., Lake Success, NY) coated



with rat anti-mouse IgG1 antibody were then added followed by a further incubation for 1 hour at 4°C. Beads were washed three times with 1.5 ml of the above buffer and bound proteins were subsequently analyzed by electrophoresis through 8% polyacrylamide gels containing SDS.

#### *Gel retention assays*

EPAS1 and ARNT cDNAs were translated in vitro as described above. Gel retention assays were performed as described previously (Semenza and Wang, 1992) using a double-stranded oligonucleotide probe radiolabeled with the Klenow fragment of *E. coli* DNA polymerase I and containing an HIF-1 $\alpha$  binding site (5'-GCCCTACGTGCTGTCTCA-3', SEQ ID NO:3) from the erythropoietin gene (Semenza and Wang, 1992). For supershift assays, a polyclonal antibody was raised against residues 1 to 10 of the human EPAS1 protein by standard methods and 1  $\mu$ l of serum was added to the gel retention reaction mixture prior to the 30 minute incubation at 4°C. A preimmune serum served as a negative antibody control.

#### *Transient transfection assays*

The pTK-RE3-luc reporter plasmid was constructed by inserting three copies of a 50-nucleotide hypoxia-inducible enhancer from the erythropoietin gene (Semenza and Wang, 1992) into pGL3-TK. The *Tie-2*- $\beta$ -galactosidase reporter gene pT2HLacZpA11.7, containing 10.3 kb of 5'-flanking DNA from the murine *Tie-2* gene was obtained from the Cardiovascular Division, Beth Israel Hospital, Boston, MA. Human embryonic kidney 293 cells (ATCC CRL#1573) were cultured in Dulbecco's modified Eagle's medium (DMEM, low glucose; Gibco-BRL) supplemented with 10% fetal calf serum. The murine hepatoma cell line Hepa1c1c7 and the c4 ARNT deficient mutant derived from this line were maintained as described previously (Legraverend et al. 1982). Approximately 24 hours before transfection, cells were inoculated in 12-well plates at a density of 120,000 cells per well. Plasmid DNA (1-10  $\mu$ g) was transfected into cells using a kit (MBS, Stratagene Corp., La Jolla, CA). Cells were allowed to recover for 3 hours at 35°C in a 3% CO<sub>2</sub> atmosphere. Where indicated, 125  $\mu$ M CoCl<sub>2</sub> (#C3169, Sigma Chem. Corp., St. Louis, MO) or 130  $\mu$ M desferrioxamine (#D9533, Sigma) were added to cells at this time and the incubation continued for an additional 16 hours in atmospheres containing 20% or 1% O<sub>2</sub>. Luciferase and  $\beta$ -galactosidase enzyme activities were determined according to the manufacturer's instructions (Tropix, Bedford, MA). Reporter gene expression was normalized by cotransfection of a  $\beta$ -galactosidase expression vector (pCMV- $\beta$ -gal) and/or to expression obtained from the pGL3-Control plasmid (Promega Corp., Madison, WI). Levels of expressed c-Myc epitope-tagged EPAS1 or HIF-1 $\alpha$  were assessed by immunoblotting with

the anti-Myc monoclonal antibody 9E10 (Santa Cruz Biotechnology, Santa Cruz, CA) using a protocol supplied by the manufacturer.

### References

- Antonsson, C., V. et al. 1995. *J. Biol. Chem.* 270:13968-13972.
- Berman, D.M., H. Tian, and D.W. Russell 1995. *Mol. Endocrinol.* 9:1561-1570.
- 5 Brogi, E., G. et al. 1996. *J. Clin. Invest.* 97:469-476.
- Burbach, K.M., A. Poland, and C.A. Bradfield 1992. *Proc. Natl. Acad. Sc. U.S.A.* 89:8185-8189.
- Chen, H.S., and G.H. Perdew 1994. *J. Biol. Chem.* 269:27554-27558.
- Citri, Y., et al. 1987. *Nature* 326:42-47.
- 10 Craig, C.M., and W.A. Bickmore 1994. *Nature Genetics* 7:376-382.
- Dumont, D.J., et al. *Genes & Dev.* 8:1897-1909.
- Dumont, D.J., et al. 1995. *Developmental Dynamics* 203:80-92.
- Dumont, D.J., et al. 1992. *Oncogene* 7:1471-1480.
- Fong, G-H., J. Reascend, M. Gertsenstein, and M.L. Breitman 1995. *Nature* 376:66-70.
- 15 Forsythe, J.A., et al. 1996. *Molec. Cell. Biol.* 16:4604-4613.
- Fukunaga, B.N., et al. 1995. *J. Biol. Chem.* 270:29270-29278.
- Gekakis, N., et al. 1995. *Science* 270:811-815.
- Hankinson, O. 1995. *Ann. Rev. Pharmacol. Toxicol.* 35:307-340.
- Henry, E.C., and T.A. Gasiewicz 1993. *Biochem. J.* 294: (Pt 1) 95-101.
- 20 Hirose, K., et al. 1996. *Cell. Biol.* 16:1706-1713.
- Hoffman, E.C., et al. 1991. *Science* 252:954-958.
- Huang, Z.J., I. Edery, and M. Rosbash 1993. *Nature* 364:259-262.
- Hunter-Ensor, M., A. Ousley, and A. Sehgal 1996. *Cell* 84:677-685.
- Isaac, D.D., and D.J. Andrew 1996. *Genes & Dev.* 10:103-117.
- 25 Jackson, F.R., T.A. Bargiello, S.H. Yun, and M.W. Young 1986. *Nature* 320:185-188.
- Jiang, B-H., E. Rue, G.L. Wang, R. Roe, and G.L. Semenza 1996. *J. Biol. Chem.* 271:17771-1778.
- Konopka, R.J., and S. Benzer 1971. *Proc. Natl. Acad. Sci. U.S.A.* 68:2112-2116.
- Lee, C., V. Parikh, T. Itsukaichi, K. Bae, and I. Edery 1996. *Science* 271:1740-1744
- 30 Legraverend, C., et al. 1982. *J. Biol. Chem.* 257:6402-6407.
- Lillie, J.W., and M.R. Green 1989. *Nature* 338:39-44.

- Lindebro, M.C., L. Poellinger, and M.L. Whitelaw 1995. *EMBO J.* 14:3528-3539.
- Maison-Pierre, P.C., M. Goldfarb, G.D. Yancopoulos, and G. Gao 1993. *Oncogene* 8:1631-1637.
- McGuire, J., et al. 1995. *J. Biol. Chem.* 270:31353-31357.
- McKnight, S.L., E.R. Gavis, R. Kingsbury, and R. Axel 1981. *Cell* 25:385-398.
- Myers, M.P., et al. 1995. *Science* 270:805-808.
- 5 Myers, M.P., et al. 1996. *Science* 271:1736-1740.
- Nambu, J.R., J.O. Lewis, K.A. Wharton, and S.T. Crews 1991. *Cell* 67:1157-1167.
- Namiki, A., et al. 1995. *J. Biol. Chem.* 270:31189-31195.
- Perdew, G.H. 1988. *J. Biol. Chem.* 263:13802-13805.
- Reisz-Porszasz, S., et al. 1994. *Mol. Cell. Biol.* 14:6075-6086.
- 10 Sato, T.N., et al. 1995. *Nature* 376:70-74.
- Sato, T.N., et al. 1993. *Proc. Natl. Acad. Sci. U.S.A.* 90:9355-9358.
- Schmidt, J.V., and C.A. Bradfield 1996. *Ann. Rev. Cell. Dev. Biol.* 12: in press.
- Schmidt, J.V., L.A. Carver, and C.A. Bradfield 1993. *J. Biol. Chem.* 268:22203-22209.
- Schnurch, H., and W. Risau 1993. *Development* 119:957-968.
- 15 Semenza, G.L., E.A. Rue, N.V. Iyer, M.G. Pang, and W.G. Kearns 1996. *Genomics* 34:437-439.
- Semenza, G.L. 1994. *Hematology-Oncology Clinics of North America* 8:863-884.
- Semenza, G.L., and G.L. Wang 1992. *Mol. Cell. Biol.* 12:5447-5454.
- Shalaby, F., et al. 1995. *Nature* 376:62-66.
- Sogawa, K., et al. 1995. *Proc. Natl. Acad. Sci. U.S.A.* 92:1936-1940.
- 20 Takeda, J., H. Yano, S. Eng, Y. Zeng, and G.I. Bell 1993. *Hum Mol. Genet.* 2:1793-1798/
- Wang, G.L., and G.L. Semenza 1995. *J. Biol. Chem.* 270:1230-1237.
- Wang, G.L., et al. 1995. *Proc. Natl. Acad. Sci. U.S.A.* 92:5510-5514.
- Wenger, R.H., et al. 1996. *Biochem. Biophys. Res. Commun.* 223:54-59.
- Wilk, R., I. Weizman, and B-Z. Shilo 1996. *Genes & Dev.* 10:93-102.
- 25 Wood, S.M., et al. 1996. *J. Biol. Chem.* 271:15117-15123.
- Yokoyama, C., et al. 1993. *Cell* 75:187-197.
- Zeng, H., Z. Qian, M.P. Myers, and M. Rosbash 1996. *Nature* 380:129-135.

## EXAMPLES

- 30 1. Protocol for high throughput EPAS1-ARNT complex formation assay.
- A. Reagents:

- Neutralite Avidin: 20 µg/ml in PBS.
- Blocking buffer: 5% BSA, 0.5% Tween 20 in PBS; 1 hour at room temperature.
- Assay Buffer: 100 mM KCl, 20 mM HEPES pH 7.6, 1 mM MgCl<sub>2</sub>, 1% glycerol, 0.5% NP-40, 50 mM β-mercaptoethanol, 1 mg/ml BSA, cocktail of protease inhibitors.
- <sup>33</sup>P EPAS1 protein 10x stock: 10<sup>-8</sup> - 10<sup>-6</sup> M "cold" EPAS1 supplemented with 200,000-250,000 cpm of labeled EPAS1 (Beckman counter). Place in the 4°C microfridge during screening.

- Protease inhibitor cocktail (1000X): 10 mg Trypsin Inhibitor (BMB # 109894), 10 mg Aprotinin (BMB # 236624), 25 mg Benzamidine (Sigma # B-6506), 25 mg Leupeptin (BMB # 1017128), 10 mg APMSF (BMB # 917575), and 2mM NaVO<sub>3</sub> (Sigma # S-6508) in 10 ml of PBS.

- ARNT: 10<sup>-7</sup> - 10<sup>-5</sup> M biotinylated ARNT in PBS.

B. Preparation of assay plates:

- Coat with 120 µl of stock N-Avidin per well overnight at 4°C.
- Wash 2 times with 200 µl PBS.
- Block with 150 µl of blocking buffer.
- Wash 2 times with 200 µl PBS.

C. Assay:

- Add 40 µl assay buffer/well.
- Add 10 µl compound or extract.
- Add 10 µl <sup>33</sup>P-EPAS1 protein (20-25,000 cpm/0.1-10 pmoles/well = 10<sup>-9</sup> - 10<sup>-7</sup> M final conc).
- Shake at 25°C for 15 minutes.
- Incubate additional 45 minutes at 25°C.
- Add 40 µl biotinylated hTFII subunit (0.1-10 pmoles/40 ul in assay buffer)
- Incubate 1 hour at room temperature.
- Stop the reaction by washing 4 times with 200 µl PBS.
- Add 150 µl scintillation cocktail.
- Count in Topcount.

D. Controls for all assays (located on each plate):

- a. Non-specific binding
- b. Soluble (non-biotinylated EPAS1) at 80% inhibition.

## 2. Protocol for high throughput human EPAS1/ARNT- DNA complex formation assay.

## A. Reagents:

- Neutralite Avidin: 20 µg/ml in PBS.
- Blocking buffer: 5% BSA, 0.5% Tween 20 in PBS; 1 hour at room temperature.
- Assay Buffer: 100 mM KCl, 20 mM HEPES pH 7.6, 1 mM MgCl<sub>2</sub>, 1% glycerol, 0.5%

5 NP-40, 50 mM β-mercaptoethanol, 1 mg/ml BSA, cocktail of protease inhibitors.

- <sup>33</sup>P human EPAS1 protein 10x stock: 10<sup>-8</sup> - 10<sup>-6</sup> M "cold" human EPAS1 subunit (p105) supplemented with 200,000-250,000 cpm of labeled human EPAS1 (Beckman counter). Place in the 4°C microfridge during screening.

10 - Protease inhibitor cocktail (1000X): 10 mg Trypsin Inhibitor (BMB # 109894), 10 mg Aprotinin (BMB # 236624), 25 mg Benzamidine (Sigma # B-6506), 25 mg Leupeptin (BMB # 1017128), 10 mg APMSF (BMB # 917575), and 2mM NaVO<sub>3</sub> (Sigma # S-6508) in 10 ml of PBS.

- DNA: 10<sup>-7</sup> - 10<sup>-4</sup> M biotinylated DNA (SEQ ID NO:3) in PBS.

- ARNT protein: 10<sup>-7</sup> - 10<sup>-5</sup> M ARNT in PBS.

## B. Preparation of assay plates:

15 - Coat with 120 µl of stock N-Avidin per well overnight at 4°C.

- Wash 2 times with 200 µl PBS.

- Block with 150 µl of blocking buffer.

- Wash 2 times with 200 µl PBS.

## C. Assay:

20 - Add 40 µl assay buffer/well.

- Add 10 µl compound or extract.

- Add 10 µl <sup>33</sup>P-h EPAS1 protein (20-25,000 cpm/0.1-10 pmoles/well = 10<sup>-9</sup>- 10<sup>-7</sup> M final).

- Add 10µl ARNT protein.

- Shake at 25°C for 15 minutes.

25 - Incubate additional 45 minutes at 25°C.

- Add 40 µl biotinylated DNA (0.1-10 pmoles/40 ul in assay buffer)

- Incubate 1 hour at room temperature.

- Stop the reaction by washing 4 times with 200 µl PBS.

- Add 150 µl scintillation cocktail.

30 - Count in Topcount.

## D. Controls for all assays (located on each plate):

- a. Non-specific binding
- b. Soluble (non-biotinylated EPAS1/ARNT combination) at 80% inhibition.

5 All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

## TABLE I

```

1 MTAD---KBKKRSSERRKESRDAARCRRSKBTEVFYELAHBLPLPHSVSSSHLDKASIMRLEISFLRTHKLLSSVCSENESEBAEADQQM NEP-1 SEQ ID NO: 5
2 MTAD---KEKKRSSBLRKEKSRDAARCRRSKETEVEFYELAHBLPLPHSVSSSHLDKASIMRLEISFLRTHKLLSSVCSENESEAEADQQM mEP-1 SEQ ID NO: 5
3 ME GAGGANDKKKISSERRKESRDAARCRRSKBSEVFYELAHQPLPHNVSSSHLDKASVMRITISYLRVRKLLDA--GDLIDSEDDMKACQM mHF SEQ ID NO: 6
4 M-----SSERRKESRDAARCRRSRRTKESEVFYELAHQPLPHNVSSSHLDKASVMRITISYLRVRKLLDA--GGLDSEDEMKACQM mHF SEQ ID NO: 7
5
188 DNL YL KAL EBOFI AVVTQDDMDI FLSENI SKFMGLTQVELTQHSIPDFITHPCDHEERENLSLKNQSGPKKSKDMSTERDFFMRMKCTVT NEP-1
189 DNL YL KAL EBOFI AVVTQDDMDI FLSENI SKFMGLTQVELTQHSIPDFITHPCDHEERENLSLKNQSGPKKSKDMSTERDFFMRMKCTVT mEP-1
189 NCFYLKALDGPVAVLTDDGDMDIYISDNVNKYMGLTQFELTQHSVPDFITHPCDHEEMREMLTHRNGLV--KKGKEQNTQRPFLRMKCTLT mHF
177 DCFYLKALDGPVAVLTDDGDMDIYISDNVNKYMGLTQFELTQHSVPDFITHPCDHEEMREMLTHRNOPV--RKKEELNTQRPFLRMKCTLT mHF
5
178 NRGRTVNLKSATWK-VLHCTGQVKVYNNCPPHNSLCGYKBPLLSCLII MCEBPI QHPSPHMDI PLDSKTFLSRHSMDMKFTYCYDDRITELIG NEP-1
178 NRGRTVNLKSATWKSVLHCTGQVRVYNNCPPHNSLCQSKBPLLSCLII MCEBPI QHPSPHMDI PLDSKTFLSRHSMDMKFTYCYDDRITELIG mEP-1
177 SRGRTMNIKSATWK-VLHCTGHIHVDYD-NSNQPCQGYKKPMTCLVLCBPIPHPSNIEIPLDSKTFLSRHSMDMKPSYCDERITELMG mHF
165 SRGRTMNIKSATWK-VLHCTGHIHVDYD-NSNQPCQGYKKPMTCLVLCBPIPHPSNIEIPLDSKTFLSRHSMDMKPSYCDERITELMG mHF
5
267 YHPBELLGRSAYEPYHALDSENMTKSHQNLCCTEQQVVSQGYRMLAKHQGYVWLBTQGTVIYNPRNLQPCIMCVNYVLSLSEI BKNDVVVFSM NEP-1
268 YHPBELLGRSAYEPYHALDSENMTKSHQNLCCTEQQVVSQGYRMLAKHQGYVWLBTQGTVIYNPRNLQPCIMCVNYVLSLSEI BKNDVVVFSM mEP-1
265 YEPEBLLGRSIEYHYHALDS DHLT KTHHDMFTKQVTTQGYRMLAKRGQYVWVEITQATVIYNTENSPQCI VCVNYVVSQI IQHDLIPSL mHF
263 YEPEBLLGRSIEYHYHALDS DHLT KTHHDMFTKQVTTQGYRMLAKRGQYVWVEITQATVIYNTENSPQCI VCVNYVVSQI IQHDLIPSL mHF
5
357 DQTHSLFKP----HLMAMNSIPDS$GKGA$V$B$KSNFLPTKL$W$P$B$LAQL$A$P$P$GD$AI$SLDF$GN-----QNEH$ESS$AYG$K$A$IL$P$P$SQ NEP-1
358 DQTEL$FKP----HLMAMNSIPDS$DDV$A$V$B$KSNLY$F$T$K$L$P$E$P$B$LAQL$A$P$P$GD$AI$SLDF$GS-----QNEH$D$P$S$AYG$K$A$IL$P$P$Q mEP-1
355 QQT$E$C$V$L$K$P$V$E$S$D$M$K$M$T$Q$L$F$T$K$V$E$----S$D$T$S$S$L$F$D$K$L$F$E$P$D$A$L$T$LL$A$A$G$D$T$II$SLDF$G$S$D$D$T$E$D$D$Q$LE$E$V$P$L$Y$N$D$V$M$L$P$S$P$N mHF
343 QQT$E$S$V$L$K$P$V$E$S$D$M$K$M$T$Q$L$F$T$K$V$E$----S$D$T$S$C$L$F$D$K$L$K$E$P$D$A$L$T$LL$A$A$G$D$T$II$SLDF$G$S$D$D$T$E$D$D$Q$LE$D$V$P$L$Y$N$D$V$M$P$F$S$S$N mHF
5
437 -----PWATE-----LR$H$ST-----Q$B$A$G$S$L$P-A$F$T$V$P$Q$A$A$P$G$S$T$T$P$S$A$T$S$S$S$C$S$C$T$P$N$S$P$E$D$Y$T$S$L$D$N$D$L$-- NEP-1
438 -----PW$G-----L$R$H$S$A-----Q$H$S$G$S$L$P-A$F$T$V$Q$A$D$T$P$G$N$T$P$S$A-S$S$S$S$C$S$C$T$P$S$P$E$D$Y$S$S$E$N$P$L$-- mEP-1
441 EKLQNI NLA$M$S$P$L$T$A$E$T$P$K$L$R$S$A$D$P$A$L$N$Q$E$V$A$L$K$E$B$N$P$E$S$LE$L$S$F$T$M$P$QIQDQ$T$P$S$D$G-S$T$R$Q$S$P$E$P$N$S$P$B$Y$C$F$Y$V$D$S$D$M$V$N mHF
429 EKL-NI NLA$M$S$P$L$P$S$T$P$K$L$R$S$A$D$P$A$L$N$Q$E$V$A$L$K$E$S$P$E$S$G$L$S$F$T$M$P$QIQDQ$P$A$S$P$S$D$G-S$T$R$Q$S$P$E$P$N$S$P$E$Y$C$F$D$V$D$S$D$M$V$N mHF

```

TABLE I-continued

497	--KI E VI E K L F A M D T E A K D C S T O I D P N E L D L E T L A P Y I P M D G H D F Q L S P I C P E B R L L A E N P Q S	---TPQHCFSA---MTNI FQPL-APVA	MEP-1
497	--KI E VI E K L F A M D T E P R D P S T Q I D F S E L D L E T L A P Y I P M D G H D F Q L S P I C P E B R L L A E N P Q S	---TPQHCFST---MTSI FQPL-TPGA	MEP-1
530	E F K L E L V E K L F A E D T E A K N P F S T Q D--T D L D L E M L A P Y I P M D--D D G Q L R S P D Q L S P L E S S A S P S Q S T V T V F Q Q T Q I Q E P T--A N A T		MEP-1
537	V F K L E L V E K L F A E D T E A K N P F S T Q D--T D L D L E M L A P Y I P M D--D D F Q L R S P D Q L S P L E S N S P S P--P S M S T V T G F Q Q T Q L Q K P T I T A T A		MEP-1
579	P H S P F L L D K P Q Q L E S K E T E P E H R P M S S I P F D A G S K A S L P P C C Q Q A S T P L S S M G R S N T Q W P D P P L H F Q P T K W A V O D Q R T E F L G A A P L G		MEP-1
579	T H G P F F L D E Y P Q Q L E S R K T E S R H W P M S S I P F D A G S K O S L S P C C Q Q A S T P L S S M G R S N T Q W P D P P L H F Q P T K W P V G D Q S A E S L G A L P V G		MEP-1
616	T T T A-----T I D E L K T V T K D R M E D I K I L I A S P S T H I H-----K E T T S A T S S P Y R D T Q S R T A S P-----N R A G K O V I E Q T E K S		MEP-1
601	T T T A-----T I D E S K T E T K D N K E D I K I L I A S P S T Q V P-----Q E T T T A K A S A Y S O T H S R T A S P-----D R A G K R V I E Q T D K A		MEP-1
669	P-----P V S P P--H V S T P K T R S A K Q F G A R G P D V L S P A M V A L S N E L E K E Q L E Y H E Q A P Q D L S G Q-----D P P Q--G S T S H L M W K R M K N L R Q G S		MEP-1
669	S W Q L E L P S A P L--H V S M F E M R S A K D F G A R G P Y M S P A M A L S N E L E K E Q L E Y H E Q A P Q D T S G Q-----D P P Q--T S S S H L M W K R M K S L M G G T		MEP-1
684	H-----P R S P N V L S V A L S Q R T T V P-----E B E I N P K T I A S Q N A Q R--E R K M E H D G S L F Q A V G I Q T L L Q Q P D D H A A T T S L S W K R V K O C K S--		MEP-1
669	H-----P R S L N--L S A T L N Q R N T V P-----E B E I N P K T I A S Q N A Q R--E R K M E H D G S L F Q A A G I Q T L L Q Q P D C A P T M S L S W K R V K G F I S--		MEP-1
748	C P L M P D E P L S A N V P N D K E T Q N P M R G L G H P L R H L P L P Q P P S A I S P G E N S K S R R P P Q C Y A T Q Y Q D Y S L S S A H K Y S Q M A S R L L G P S E B S Y L L P		MEP-1
753	C P L M P D K T I S A N M A P D E F T Q K S M R G L G Q P L R H L P P P Q P P S T R S S O E N A K T O P P P Q C Y A S Q F Q D Y O P P O A Q Y S Q V A S H L L G P S F E P Y L L P		MEP-1
761	-----S E Q N G M E H Q T I I L I P-----S E Q N G M E H Q T I I L I P-----S D L A C R L L G Q S M D E S G L P		MEP-1
745	-----S E Q N G M E H Q T I I L I P-----S E Q N G M E H Q T I I L I P-----S D L A C R L L G Q S M D V S G L P		MEP-1
838	E L T R Y D C E V N V P V L Q S S T L I Q C G D L L R A L D Q A T		MEP-1
843	E L T R Y D C E V N V P V P G S S T L I Q C R D L L R A L D Q A T		MEP-1
794	Q L T S Y D C E V N A P I Q Q S R N L L Q C E B L L R A L D Q V N		MEP-1
778	Q L T S Y D C E V N A P I Q Q S R N L L Q C E B L L R A L D Q V N		MEP-1



## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: McKnight, Steven L.

Russell, David W.

Tian, Hui

5 (ii) TITLE OF INVENTION: Endothelial PAS Domain Protein

(iii) NUMBER OF SEQUENCES: 7

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: SCIENCE &amp; TECHNOLOGY LAW GROUP

(B) STREET: 268 BUSH STREET, SUITE 3200

10 (C) CITY: SAN FRANCISCO

(D) STATE: CALIFORNIA

(E) COUNTRY: USA

(F) ZIP: 94104

(v) COMPUTER READABLE FORM:

15 (A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

20 (A) APPLICATION NUMBER: US 08/785,241

(B) FILING DATE: 17-JAN-1997

(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: OSMAN, RICHARD A

25 (B) REGISTRATION NUMBER: 36,627

(C) REFERENCE/DOCKET NUMBER: UTSD:1229

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (415) 343-4341

(B) TELEFAX: (415) 343-4342

30

## (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2816 base pairs

(B) TYPE: nucleic acid

35 (C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

	CCTGACTGCG CGGGGCGCTC GGGACCTGCG CGCACCTCGG ACCTTCACCA CCCGCCCCGGG	60
	CCGCGGGGAG CGGACGAGGG CCACAGCCCC CCACCCGCCA GGGAGCCCAG GTGCTCGGCG	120
	TCTGAACGTC TCAAAGGGCC ACAGCGACAA TGACAGCTGA CAAGGAGAAG AAAAGGAGTA	180
	GCTCGGAGAG GAGGAAGGAG AAGTCCCGGG ATGCTGCGCG GTGCCGGCGG AGCAAGGAGA	240
5	CGGAGGTGTT CTATGAGCTG GCCCATGAGC TGCCTCTGCC CCACAGTGTG AGCTCCCATC	300
	TGGACAAGGC CTCCATCATG CGACTGGAAA TCAGCTTCCT GCGAACACAC AAGCTCCTCT	360
	CCTCAGTTTG CTCTGAAAC GAGTCCGAAG CCGAAGCTGA CCAGCAGATG GACAACTTGT	420
	ACCTGAAAGC CTTGGAGGGT TTCATTGCCG TGGTGACCCA AGATGGCGAC ATGATCTTTC	480
	TGTCAGAAAA CATCAGCAAG TTCATGGGAC TTACACAGGT GGAGCTAACA GGACATAGTA	540
10	TCTTTGACTT CACTCATCCC TGCGACCATG AGGAGATTCTG TGAGAACCTG AGTCTCAAAA	600
	ATGGCTCTGG TTTTGGGAAA AAAAGCAAAG ACATGTCCAC AGAGCGGGAC TTCTTCATGA	660
	GGATGAAGTG CACGGTCACC AACAGAGGCC GTACTGTCAA CCTCAAGTCA GCCACCTGGA	720
	AGGTCTTGCA CTGCACGGGC CAGGTGAAAG TCTACAACAA CTGCCCTCCT CACAATAGTC	780
	TGTGTGGCTA CAAGGAGCCC CTGCTGTCCT GCCTCATCAT CATGTGTGAA CCAATCCAGC	840
15	ACCCATCCCA CATGGACATC CCCCTGGATA GCAAGACCTT CCTGAGCCGC CACAGCATGG	900
	ACATGAAGTT CACCTACTGT GATGACAGAA TCACAGAACT GATTGGTTAC CACCCTGAGG	960
	AGCTGCTTGG CCGCTCAGCC TATGAATTCT ACCATGCGCT AGACTCCGAG AACATGACCA	1020
	AGAGTCACCA GAACTTGTGC ACCAAGGGTC AGGTAGTAAG TGGCCAGTAC CGGATGCTCG	1080
	CAAAGCATGG GGGCTACGTG TGGCTGGAGA CCCAGGGGAC GGTCATCTAC AACCCCTCGCA	1140
20	ACCTGCAGCC CCAGTGCATC ATGTGTGTCA ACTACGTCCT GAGTGAGATT GAGAAGAATG	1200
	ACGTGGTGTG CTCCATGGAC CAGACTGAAT CCCTGTTCAA GCCCCACCTG ATGGCCATGA	1260
	ACAGCATCTT TGATAGCAGT GGCAAGGGGG CTGTGTCTGA GAAGAGTAAC TTCCTATTCA	1320
	CCAAGCTAAA GGAGGAGCCC GAGGAGCTGG CCCAGCTGGC TCCCACCCCA GGAGACGCCA	1380
	TCATCTCTCT GGATTTCTGGG AATCAGAACT TCGAGGAGTC CTCAGCCTAT GGCAAGGCCA	1440
25	TCCTGCCCCC GAGCCAGCCA TGGGCCACGG AGTTGAGGAG CCACAGCACC CAGAGCGAGG	1500
	CTGGGAGCCT GCCTGCCTTC ACCGTGCCCC AGGCAGCTGC CCCGGGCAGC ACCACCCCA	1560
	GTGCCACCAG CAGCAGCAGC AGCTGCTCCA CGCCCAATAG CCCTGAAGAC TATTACACAT	1620
	CTTTGGATAA CGACCTGAAG ATTGAAGTGA TTGAGAAGCT CTTCGCCATG GACACAGAGG	1680
	CCAAGGACCA ATGCAGTACC CAGACGGATT TCAATGAGCT GGAATTGGAG AACTTGGCAC	1740
30	CCTATATCCC CATGGACGGG GAAGACTTCC AGCTAAGCCC CATCTGCCCC GAGGAGCGGC	1800
	TCTTGGCGGA GAACCCACAG TCCACCCCCC AGCACTGCTT CAGTGCCATG ACAAACATCT	1860
	TCCAGCCACT GGCCCTGTG GCCCCGCACA GTCCCTTCCT CCTGGACAAG TTTCAGCAGC	1920
	AGCTGGAGAG CAAGAAGACA GAGCCCGAGC ACCGGCCCAT GTCCTCCATC TTCTTTGATG	1980
	CCGGAAGCAA AGCATCCCTG CCACCGTGCT GTGGCCAGGC CAGCACCCCT CTCTCTTCCA	2040
35	TGGGGGGCAG ATCCAATACC CAGTGGCCCC CAGATCCACC ATTACATTTT GGGCCCCACAA	2100
	AGTGGGCCGT CGGGGATCAG CGCACAGAGT TCTTGGGAGC AGCGCCGTTG GGGCCCCCTG	2160
	TCTCTCCACC CCATGTCTCC ACCTTCAAGA CAAGGTCTGC AAAGGGTTTT GGGGCTCGAG	2220

GCCCAGACGT GCTGAGTCCG GCCATGGTAG CCCTCTCCAA CAAGCTGAAG CTGAAGCGAC 2280  
 AGCTGGAGTA TGAAGAGCAA GCCTTCCAGG ACCTGAGCGG GGGGGACCCA CCTGGTGGCA 2340  
 GCACCTCACA TTTGATGTGG AAACGGATGA AGAACCTCAG GGGTGGGAGC TGCCCTTTGA 2400  
 TGCCGGACAA GCCACTGAGC GCAAATGTAC CCAATGATAA GTTCACCCAA AACCCCATGA 2460  
 GGGGCCTGGG CCATCCCCTG AGACATCTGC CGCTGCCACA GCCTCCATCT GCCATCAGTC 2520  
 5 CCGGGGAGAA CAGCAAGAGC AGGTTCCCCC CACAGTGCTA CGCCACCCAG TACCAGGACT 2580  
 ACAGCCTGTC GTCAGCCCAC AAGGTGTCAG GCATGGCAAG CCGGCTGCTC GGGCCCTCAT 2640  
 TTGAGTCCTA CCTGCTGCCC GAACTGACCA GATATGACTG TGAGGTGAAC GTGCCCCGTGC 2700  
 TGGGAAGCTC CACGCTCCTG CAAGGAGGGG ACCTCCTCAG AGCCCTGGAC CAGGCCACCT 2760  
 GAGCCAGGCC TTCTACCTGG GCAGCACCTC TGCCGACGCC GTCCCACCAG CTTCAC 2816

10

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3031 base pairs

(B) TYPE: nucleic acid

15

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

20 CGACAGAGAG CTGCGGAGGG CCACAGCAAA GAGAGCGGCT GCAGCCCCTA CGGGGTAAAG 60  
 GAACCCAGGT GCTCCGGGTC TCGGAGGGCC ACGGCGACAA TGACAGCTGA CAAGGAGAAA 120  
 AAAAGGAGCA GCTCAGAGCT GAGGAAGGAG AAATCCCGTG ATGCCGCGAG GTGCCGGCGC 180  
 AGCAAGGAGA CGGAGGTCTT CTATGAGTTG GCTCATGAGT TGCCCTTGCC TCACAGTGTG 240  
 AGTCCCAACC TGGACAAAGC CTCCATCATG CGCCTGGCCA TCAGCTTCCT TCGGACACAT 300  
 AAGCTCCTGT CCTCAGTCTG CTCTGAAAAT GAATCTGAAG CTGAGGCCGA CCAGCAAATG 360  
 25 GATAACTTGT ACCTGAAAGC CTTGGAGGGT TTCATTGCTG TGGTGACCCA AGACGGTGAC 420  
 ATGATCTTTC TGTCGGAAAA CATCAGCAAG TTCATGGGAC TTACTCAGGT AGAACTAACA 480  
 GGACACAGCA TCTTTGACTT CACTCATCCT TGCGACCATG AAGAGATCCG TGAGAACCTG 540  
 ACTCTCAAAA ACGGCTCTGG TTTTGGGAAG AAGAGCAAAG ACGTGTCCAC CGAGCGTGAC 600  
 TTCTTCATGA GGATGAAGTG CACGGTCACC AACAGAGGCC GGA CTGTCAA CCTCAAGTCG 660  
 30 GCCACCTGGA AGTCCGTCCT GCACTGCACC GGGCAAGTGA GAGTCTACAA CAACTGCCCC 720  
 CCTCACAGTA GCCTCTGTGG CTCCAAGGAG CCCCTGCTGT CCTGCCTTAT CATCATGTGT 780  
 GAGCCAATCC AGCACCCATC CCACATGGAC ATCCCCCTGG ACAGCAAGAC TTTCTGAGC 840  
 CGCCACAGCA TGGACATGAA GTTCACCTAC TGTGACGACA GAATCTTGGA ACTGATTGGT 900  
 TACCACCCCG AGGAGCTACT TGGACGCTCT GCCTATGAGT TTTACCATGC CCTGGATTCTG 960  
 35 GAGAACATGA CAAAAGTCA CCAGAACTTG TGCACCAAGG GGCAGGTGGT ATCTGGCCAG 1020  
 TACCGGATGC TAGCCAAACA CGGAGGATAT GTGTGGCTGG AGACCCAGGG GACGGTCATC 1080  
 TACAACCCCC GCAACCTGCA GCCTCAGTGT ATCATGTGTG TCAACTATGT GCTGAGTGAG 1140

	ATCGAGAAGA	ACGACGTGGT	GTTCTCCATG	GACCAGACCG	AATCCCTGTT	CAAGCCACAC	1200
	CTGATGGCCA	TGAACAGCAT	CTTTGACAGC	AGTGACGATG	TGGCTGTAAC	TGAGAAGAGC	1260
	AACTACCTGT	TCACCAAAC	GAAGGAGGAG	CCCGAGGAAC	TGGCCCAGTT	GGCCCCCACC	1320
	CCAGGAGATG	CCATTATTTC	TCTCGATTTC	GGAAGCCAGA	ACTTCGATGA	ACCCTCAGCC	1380
	TATGGCAAGG	CCATCCTTCC	CCCGGGCCAG	CCATGGGTCT	CGGGGCTGAG	GAGCCACAGT	1440
5	GCCCAGAGCG	AGTCCGGGAG	CCTGCCAGCC	TTCCTGTGTC	CCCAGGCAGA	CACCCCAGGG	1500
	AACACTACAC	CCAGTGCTTC	AAGCAGCAGT	AGCTGCTCCA	CGCCCAGCAG	CCCTGAGGAC	1560
	TACTATTTCAT	CCTTGGAGAA	TCCCTTGAAG	ATCGAAGTGA	TTGAGAAGCT	TTTCGCCATG	1620
	GACACGGAGC	CGAGGGACCC	GGGCAGTACC	CAGACGGACT	TCAGTGAAC	GGATTGAG	1680
	ACCTTGGCAC	CCTACATCCC	TATGGACGGC	GAGGACTTCC	AGCTGAGCCC	CATCTGCCCA	1740
10	GAGGAGCCGC	TCATGCCAGA	GAGCCCCCAG	CCCACCCCCC	AGCACTGCTT	CAGTACCATG	1800
	ACCAGCATCT	TCCAGCCGCT	CACCCCGGGG	GCCACCCACG	GCCCCCTTCT	CCTCGATAAG	1860
	TACCCGCAGC	AGTTGGAAAG	CAGGAAGACA	GAGTCTGAGC	ACTGGCCCAT	GTCTTCCATC	1920
	TTCTTTGATG	CTGGGAGCAA	AGGGTCCCTG	TCTCCATGCT	GTGGCCAGGC	CAGCACCCCT	1980
	CTCTCTTCTA	TGGGAGGCAG	ATCCAACACG	CAGTGGCCCC	CGGATCCACC	ATTACATTTC	2040
15	GGCCCTACTA	AGTGGCCTGT	GGGTGATCAG	AGTGCTGAAT	CCCTGGGAGC	CCTGCCGGTG	2100
	GGGTCATGGC	AGTTGGAAC	TCCGAGCGCC	CCGCTTCATG	TCTCCATGTT	CAAGATGAGG	2160
	TCTGCAAAGG	ACTTCGGGGC	CCGAGGTCCA	TACATGATGA	GCCCAGCCAT	GATCGCCCTG	2220
	TCCAACAAGC	TGAAGCTAAA	GCGGCAGCTG	GAGTATGAGG	AGCAAGCCTT	CCAAGACACA	2280
	AGCGGGGGGG	ACCCTCCAGG	CACCAGCAGT	TCACACTTGA	TGTGGAAACG	TATGAAGAGC	2340
20	CTCATGGGCG	GGACCTGTCC	TTTGATGCCT	GACAAGACCA	TCAGTGCGAA	CATGGCCCCC	2400
	GATGAATTCA	CCCAAAAATC	TATGAGAGGC	CTGGGCCAGC	CACTGAGACA	CCTGCCACCT	2460
	CCCCAGCCAC	CATCTACCAG	GAGCTCAGGG	GAGAACGCCA	AGACTGGGTT	CCCGCCACAG	2520
	TGCTATGCCT	CCCAGTTCCA	GGACTACGGT	CCTCCAGGAG	CTCAAAAGGT	GTCAGGCGTG	2580
	GCCAGTCGAC	TGCTGGGGCC	ATCGTTTCGAG	CCTTACCTGT	TGCCGGAAC	GACCAGATAT	2640
25	GACTGTGAGG	TGAACGTGCC	CGTGCCTGGA	AGCTCCACAC	TCCTGCAGGG	GAGAGACCTT	2700
	CTCAGAGCTC	TGGACCAGGC	CACCTGAGCC	AGGGCCTCTG	GCCGGGCATG	CCCCTGCCTG	2760
	CCCCGCCGTC	TTGACCTGCC	AGCTTCACTT	CCATCTGTGT	TGCTATTAGG	TATCTCTAAC	2820
	ACCAGCACAC	TTCTTACGAG	ATGTACTCAA	CCTGGCCTAC	TGGCCAGGTC	ACCAAGCAGT	2880
	GGCCTTTATC	TGACATGCTC	ACTTTATTAT	CCATGTTTTA	AAAATACATA	GTTGTTGTAC	2940
30	CTGCTATGTT	TTACCGTTGA	TGAAAGTGTT	CTGAAATTTT	ATAAGATTTC	CCCCTCCCTC	3000
	CCTCCCTTGA	ATTACTTCTA	ATTTATATTC	C			3031

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

35

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GCCCTACGTG CTGTCTCA

18

5 (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 870 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Thr Ala Asp Lys Glu Lys Lys Arg Ser Ser Ser Glu Arg Arg Lys

1 5 10 15

15 Glu Lys Ser Arg Asp Ala Ala Arg Cys Arg Arg Ser Lys Glu Thr Glu

20 25 30

Val Phe Tyr Glu Leu Ala His Glu Leu Pro Leu Pro His Ser Val Ser

35 40 45

Ser His Leu Asp Lys Ala Ser Ile Met Arg Leu Glu Ile Ser Phe Leu

20 50 55 60

Arg Thr His Lys Leu Leu Ser Ser Val Cys Ser Glu Asn Glu Ser Glu

65 70 75 80

Ala Glu Ala Asp Gln Gln Met Asp Asn Leu Tyr Leu Lys Ala Leu Glu

85 90 95

25 Gly Phe Ile Ala Val Val Thr Gln Asp Gly Asp Met Ile Phe Leu Ser

100 105 110

Glu Asn Ile Ser Lys Phe Met Gly Leu Thr Gln Val Glu Leu Thr Gly

115 120 125

His Ser Ile Phe Asp Phe Thr His Pro Cys Asp His Glu Glu Ile Arg

30 130 135 140

Glu Asn Leu Ser Leu Lys Asn Gly Ser Gly Phe Gly Lys Lys Ser Lys

145 150 155 160

Asp Met Ser Thr Glu Arg Asp Phe Phe Met Arg Met Lys Cys Thr Val

165 170 175

35 Thr Asn Arg Gly Arg Thr Val Asn Leu Lys Ser Ala Thr Trp Lys Val

180 185 190

Leu His Cys Thr Gly Gln Val Lys Val Tyr Asn Asn Cys Pro Pro His

	195	200	205
	Asn Ser Leu Cys Gly Tyr Lys Glu Pro Leu Leu Ser Cys Leu Ile Ile		
	210	215	220
	Met Cys Glu Pro Ile Gln His Pro Ser His Met Asp Ile Pro Leu Asp		
	225	230	235 240
5	Ser Lys Thr Phe Leu Ser Arg His Ser Met Asp Met Lys Phe Thr Tyr		
	245	250	255
	Cys Asp Asp Arg Ile Thr Glu Leu Ile Gly Tyr His Pro Glu Glu Leu		
	260	265	270
	Leu Gly Arg Ser Ala Tyr Glu Phe Tyr His Ala Leu Asp Ser Glu Asn		
10	275	280	285
	Met Thr Lys Ser His Gln Asn Leu Cys Thr Lys Gly Gln Val Val Ser		
	290	295	300
	Gly Gln Tyr Arg Met Leu Ala Lys His Gly Gly Tyr Val Trp Leu Glu		
	305	310	315 320
15	Thr Gln Gly Thr Val Ile Tyr Asn Pro Arg Asn Leu Gln Pro Gln Cys		
	325	330	335
	Ile Met Cys Val Asn Tyr Val Leu Ser Glu Ile Glu Lys Asn Asp Val		
	340	345	350
	Val Phe Ser Met Asp Gln Thr Glu Ser Leu Phe Lys Pro His Leu Met		
20	355	360	365
	Ala Met Asn Ser Ile Phe Asp Ser Ser Gly Lys Gly Ala Val Ser Glu		
	370	375	380
	Lys Ser Asn Phe Leu Phe Thr Lys Leu Lys Glu Glu Pro Glu Glu Leu		
	385	390	395 400
25	Ala Gln Leu Ala Pro Thr Pro Gly Asp Ala Ile Ile Ser Leu Asp Phe		
	405	410	415
	Gly Asn Gln Asn Phe Glu Glu Ser Ser Ala Tyr Gly Lys Ala Ile Leu		
	420	425	430
	Pro Pro Ser Gln Pro Trp Ala Thr Glu Leu Arg Ser His Ser Thr Gln		
30	435	440	445
	Ser Glu Ala Gly Ser Leu Pro Ala Phe Thr Val Pro Gln Ala Ala Ala		
	450	455	460
	Pro Gly Ser Thr Thr Pro Ser Ala Thr Ser Ser Ser Ser Ser Cys Ser		
	465	470	475 480
35	Thr Pro Asn Ser Pro Glu Asp Tyr Tyr Thr Ser Leu Asp Asn Asp Leu		
	485	490	495
	Lys Ile Glu Val Ile Glu Lys Leu Phe Ala Met Asp Thr Glu Ala Lys		

	500	505	510
	Asp Gln Cys Ser Thr Gln Thr	Asp Phe Asn Glu Leu Asp	Leu Glu Thr
	515	520	525
	Leu Ala Pro Tyr Ile Pro Met	Asp Gly Glu Asp Phe Gln	Leu Ser Pro
	530	535	540
5	Ile Cys Pro Glu Glu Arg Leu Leu	Ala Glu Asn Pro Gln Ser Thr	Pro
	545	550	555 560
	Gln His Cys Phe Ser Ala Met Thr	Asn Ile Phe Gln Pro Leu Ala	Pro
	565	570	575
	Val Ala Pro His Ser Pro Phe Leu Leu	Asp Lys Phe Gln Gln Gln	Leu
10	580	585	590
	Glu Ser Lys Lys Thr Glu Pro Glu His	Arg Pro Met Ser Ser Ile Phe	
	595	600	605
	Phe Asp Ala Gly Ser Lys Ala Ser Leu	Pro Pro Cys Cys Gly Gln Ala	
	610	615	620
15	Ser Thr Pro Leu Ser Ser Met Gly Gly	Arg Ser Asn Thr Gln Trp Pro	
	625	630	635 640
	Pro Asp Pro Pro Leu His Phe Gly Pro	Thr Lys Trp Ala Val Gly Asp	
	645	650	655
	Gln Arg Thr Glu Phe Leu Gly Ala Ala	Pro Leu Gly Pro Pro Val Ser	
20	660	665	670
	Pro Pro His Val Ser Thr Phe Lys Thr	Arg Ser Ala Lys Gly Phe Gly	
	675	680	685
	Ala Arg Gly Pro Asp Val Leu Ser Pro	Ala Met Val Ala Leu Ser Asn	
	690	695	700
25	Lys Leu Lys Leu Lys Arg Gln Leu Glu	Tyr Glu Glu Gln Ala Phe Gln	
	705	710	715 720
	Asp Leu Ser Gly Gly Asp Pro Pro Gly	Gly Ser Thr Ser His Leu Met	
	725	730	735
	Trp Lys Arg Met Lys Asn Leu Arg Gly	Gly Ser Cys Pro Leu Met Pro	
30	740	745	750
	Asp Lys Pro Leu Ser Ala Asn Val Pro	Asn Asp Lys Phe Thr Gln Asn	
	755	760	765
	Pro Met Arg Gly Leu Gly His Pro Leu	Arg His Leu Pro Leu Pro Gln	
	770	775	780
35	Pro Pro Ser Ala Ile Ser Pro Gly Glu	Asn Ser Lys Ser Arg Phe Pro	
	785	790	795 800
	Pro Gln Cys Tyr Ala Thr Gln Tyr Gln	Asp Tyr Ser Leu Ser Ser Ala	

805 810 815  
 His Lys Val Ser Gly Met Ala Ser Arg Leu Leu Gly Pro Ser Phe Glu  
 820 825 830  
 Ser Tyr Leu Leu Pro Glu Leu Thr Arg Tyr Asp Cys Glu Val Asn Val  
 835 840 845  
 5 Pro Val Leu Gly Ser Ser Thr Leu Leu Gln Gly Gly Asp Leu Leu Arg  
 850 855 860  
 Ala Leu Asp Gln Ala Thr  
 865 870

10 (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 875 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 15 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Thr Ala Asp Lys Glu Lys Lys Arg Ser Ser Ser Glu Leu Arg Lys  
 1 5 10 15  
 20 Glu Lys Ser Arg Asp Ala Ala Arg Cys Arg Arg Ser Lys Glu Thr Glu  
 20 25 30  
 Val Phe Tyr Glu Leu Ala His Glu Leu Pro Leu Pro His Ser Val Ser  
 35 40 45  
 Ser His Leu Asp Lys Ala Ser Ile Met Arg Leu Ala Ile Ser Phe Leu  
 50 55 60  
 25 Arg Thr His Lys Leu Leu Ser Ser Val Cys Ser Glu Asn Glu Ser Glu  
 65 70 75 80  
 Ala Glu Ala Asp Gln Gln Met Asp Asn Leu Tyr Leu Lys Ala Leu Glu  
 85 90 95  
 30 Gly Phe Ile Ala Val Val Thr Gln Asp Gly Asp Met Ile Phe Leu Ser  
 100 105 110  
 Glu Asn Ile Ser Lys Phe Met Gly Leu Thr Gln Val Glu Leu Thr Gly  
 115 120 125  
 His Ser Ile Phe Asp Phe Thr His Pro Cys Asp His Glu Glu Ile Arg  
 130 135 140  
 35 Glu Asn Leu Thr Leu Lys Asn Gly Ser Gly Phe Gly Lys Lys Ser Lys  
 145 150 155 160



Asp Val Ser Thr Glu Arg Asp Phe Phe Met Arg Met Lys Cys Thr Val  
 165 170 175  
 Thr Asn Arg Gly Arg Thr Val Asn Leu Lys Ser Ala Thr Trp Lys Ser  
 180 185 190  
 Val Leu His Cys Thr Gly Gln Val Arg Val Tyr Asn Asn Cys Pro Pro  
 195 200 205  
 His Ser Ser Leu Cys Gly Ser Lys Glu Pro Leu Leu Ser Cys Leu Ile  
 210 215 220  
 Ile Met Cys Glu Pro Ile Gln His Pro Ser His Met Asp Ile Pro Leu  
 225 230 235 240  
 Asp Ser Lys Thr Phe Leu Ser Arg His Ser Met Asp Met Lys Phe Thr  
 245 250 255  
 Tyr Cys Asp Asp Arg Ile Leu Glu Leu Ile Gly Tyr His Pro Glu Glu  
 260 265 270  
 Leu Leu Gly Arg Ser Ala Tyr Glu Phe Tyr His Ala Leu Asp Ser Glu  
 275 280 285  
 Asn Met Thr Lys Ser His Gln Asn Leu Cys Thr Lys Gly Gln Val Val  
 290 295 300  
 Ser Gly Gln Tyr Arg Met Leu Ala Lys His Gly Gly Tyr Val Trp Leu  
 305 310 315 320  
 Glu Thr Gln Gly Thr Val Ile Tyr Asn Pro Arg Asn Leu Gln Pro Gln  
 325 330 335  
 Cys Ile Met Cys Val Asn Tyr Val Leu Ser Glu Ile Glu Lys Asn Asp  
 340 345 350  
 Val Val Phe Ser Met Asp Gln Thr Glu Ser Leu Phe Lys Pro His Leu  
 355 360 365  
 Met Ala Met Asn Ser Ile Phe Asp Ser Ser Asp Asp Val Ala Val Thr  
 370 375 380  
 Glu Lys Ser Asn Tyr Leu Phe Thr Lys Leu Lys Glu Glu Pro Glu Glu  
 385 390 395 400  
 Leu Ala Gln Leu Ala Pro Thr Pro Gly Asp Ala Ile Ile Ser Leu Asp  
 405 410 415  
 Phe Gly Ser Gln Asn Phe Asp Glu Pro Ser Ala Tyr Gly Lys Ala Ile  
 420 425 430  
 Leu Pro Pro Gly Gln Pro Trp Val Ser Gly Leu Arg Ser His Ser Ala  
 435 440 445  
 Gln Ser Glu Ser Gly Ser Leu Pro Ala Phe Thr Val Pro Gln Ala Asp  
 450 455 460

Thr Pro Gly Asn Thr Thr Pro Ser Ala Ser Ser Ser Ser Cys Ser  
 465 470 475 480  
 Thr Pro Ser Ser Pro Glu Asp Tyr Tyr Ser Ser Leu Glu Asn Pro Leu  
 485 490 495  
 Lys Ile Glu Val Ile Glu Lys Leu Phe Ala Met Asp Thr Glu Pro Arg  
 500 505 510  
 Asp Pro Gly Ser Thr Gln Thr Asp Phe Ser Glu Leu Asp Leu Glu Thr  
 515 520 525  
 Leu Ala Pro Tyr Ile Pro Met Asp Gly Glu Asp Phe Gln Leu Ser Pro  
 530 535 540  
 Ile Cys Pro Glu Glu Pro Leu Met Pro Glu Ser Pro Gln Pro Thr Pro  
 545 550 555 560  
 Gln His Cys Phe Ser Thr Met Thr Ser Ile Phe Gln Pro Leu Thr Pro  
 565 570 575  
 Gly Ala Thr His Gly Pro Phe Phe Leu Asp Lys Tyr Pro Gln Gln Leu  
 580 585 590  
 Glu Ser Arg Lys Thr Glu Ser Glu His Trp Pro Met Ser Ser Ile Phe  
 595 600 605  
 Phe Asp Ala Gly Ser Lys Gly Ser Leu Ser Pro Cys Cys Gly Gln Ala  
 610 615 620  
 Ser Thr Pro Leu Ser Ser Met Gly Gly Arg Ser Asn Thr Gln Trp Pro  
 625 630 635 640  
 Pro Asp Pro Pro Leu His Phe Gly Pro Thr Lys Trp Pro Val Gly Asp  
 645 650 655  
 Gln Ser Ala Glu Ser Leu Gly Ala Leu Pro Val Gly Ser Trp Gln Leu  
 660 665 670  
 Glu Leu Pro Ser Ala Pro Leu His Val Ser Met Phe Lys Met Arg Ser  
 675 680 685  
 Ala Lys Asp Phe Gly Ala Arg Gly Pro Tyr Met Met Ser Pro Ala Met  
 690 695 700  
 Ile Ala Leu Ser Asn Lys Leu Lys Leu Lys Arg Gln Leu Glu Tyr Glu  
 705 710 715 720  
 Glu Gln Ala Phe Gln Asp Thr Ser Gly Gly Asp Pro Pro Gly Thr Ser  
 725 730 735  
 Ser Ser His Leu Met Trp Lys Arg Met Lys Ser Leu Met Gly Gly Thr  
 740 745 750  
 Cys Pro Leu Met Pro Asp Lys Thr Ile Ser Ala Asn Met Ala Pro Asp  
 755 760 765

Glu Phe Thr Gln Lys Ser Met Arg Gly Leu Gly Gln Pro Leu Arg His  
 770 775 780  
 Leu Pro Pro Pro Gln Pro Pro Ser Thr Arg Ser Ser Gly Glu Asn Ala  
 785 790 795 800  
 Lys Thr Gly Phe Pro Pro Gln Cys Tyr Ala Ser Gln Phe Gln Asp Tyr  
 805 810 815  
 Gly Pro Pro Gly Ala Gln Lys Val Ser Gly Val Ala Ser Arg Leu Leu  
 820 825 830  
 Gly Pro Ser Phe Glu Pro Tyr Leu Leu Pro Glu Leu Thr Arg Tyr Asp  
 835 840 845  
 Cys Glu Val Asn Val Pro Val Pro Gly Ser Ser Thr Leu Leu Gln Gly  
 850 855 860  
 Arg Asp Leu Leu Arg Ala Leu Asp Gln Ala Thr  
 865 870 875

15 (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 826 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Glu Gly Ala Gly Gly Ala Asn Asp Lys Lys Lys Ile Ser Ser Glu  
 1 5 10 15  
 Arg Arg Lys Glu Lys Ser Arg Asp Ala Ala Arg Ser Arg Arg Ser Lys  
 20 25 30  
 Glu Ser Glu Val Phe Tyr Glu Leu Ala His Gln Leu Pro Leu Pro His  
 35 40 45  
 Asn Val Ser Ser His Leu Asp Lys Ala Ser Val Met Arg Leu Thr Ile  
 50 55 60  
 Ser Tyr Leu Arg Val Arg Lys Leu Leu Asp Ala Gly Asp Leu Asp Ile  
 65 70 75 80  
 Glu Asp Asp Met Lys Ala Gln Met Asn Cys Phe Tyr Leu Lys Ala Leu  
 85 90 95  
 Asp Gly Phe Val Met Val Leu Thr Asp Asp Gly Asp Met Ile Tyr Ile  
 100 105 110  
 Ser Asp Asn Val Asn Lys Tyr Met Gly Leu Thr Gln Phe Glu Leu Thr

115 120 125  
 Gly His Ser Val Phe Asp Phe Thr His Pro Cys Asp His Glu Glu Met  
 130 135 140  
 Arg Glu Met Leu Thr His Arg Asn Gly Leu Val Lys Lys Gly Lys Glu  
 145 150 155 160  
 5 Gln Asn Thr Gln Arg Ser Phe Phe Leu Arg Met Lys Cys Thr Leu Thr  
 165 170 175  
 Ser Arg Gly Arg Thr Met Asn Ile Lys Ser Ala Thr Trp Lys Val Leu  
 180 185 190  
 His Cys Thr Gly His Ile His Val Tyr Asp Thr Asn Ser Asn Gln Pro  
 10 195 200 205  
 Gln Cys Gly Tyr Lys Lys Pro Pro Met Thr Cys Leu Val Leu Ile Cys  
 210 215 220  
 Glu Pro Ile Pro His Pro Ser Asn Ile Glu Ile Pro Leu Asp Ser Lys  
 225 230 235 240  
 15 Thr Phe Leu Ser Arg His Ser Leu Asp Met Lys Phe Ser Tyr Cys Asp  
 245 250 255  
 Glu Arg Ile Thr Glu Leu Met Gly Tyr Glu Pro Glu Glu Leu Leu Gly  
 260 265 270  
 Arg Ser Ile Tyr Glu Tyr Tyr His Ala Leu Asp Ser Asp His Leu Thr  
 20 275 280 285  
 Lys Thr His His Asp Met Phe Thr Lys Gly Gln Val Thr Thr Gly Gln  
 290 295 300  
 Tyr Arg Met Leu Ala Lys Arg Gly Gly Tyr Val Trp Val Glu Thr Gln  
 305 310 315 320  
 25 Ala Thr Val Ile Tyr Asn Thr Lys Asn Ser Gln Pro Gln Cys Ile Val  
 325 330 335  
 Cys Val Asn Tyr Val Val Ser Gly Ile Ile Gln His Asp Leu Ile Phe  
 340 345 350  
 Ser Leu Gln Gln Thr Glu Cys Val Leu Lys Pro Val Glu Ser Ser Asp  
 30 355 360 365  
 Met Lys Met Thr Gln Leu Phe Thr Lys Val Glu Ser Glu Asp Thr Ser  
 370 375 380  
 Ser Leu Phe Asp Lys Leu Lys Lys Glu Pro Asp Ala Leu Thr Leu Leu  
 385 390 395 400  
 35 Ala Pro Ala Ala Gly Asp Thr Ile Ile Ser Leu Asp Phe Gly Ser Asn  
 405 410 415  
 Asp Thr Glu Thr Asp Asp Gln Gln Leu Glu Glu Val Pro Leu Tyr Asn

420 425 430  
 Asp Val Met Leu Pro Ser Pro Asn Glu Lys Leu Gln Asn Ile Asn Leu  
 435 440 445  
 Ala Met Ser Pro Leu Pro Thr Ala Glu Thr Pro Lys Pro Leu Arg Ser  
 450 455 460  
 5 Ser Ala Asp Pro Ala Leu Asn Gln Glu Val Ala Leu Lys Leu Glu Pro  
 465 470 475 480  
 Asn Pro Glu Ser Leu Glu Leu Ser Phe Thr Met Pro Gln Ile Gln Asp  
 485 490 495  
 Gln Thr Pro Ser Pro Ser Asp Gly Ser Thr Arg Gln Ser Ser Pro Glu  
 10 500 505 510  
 Pro Asn Ser Pro Ser Glu Tyr Cys Phe Tyr Val Asp Ser Asp Met Val  
 515 520 525  
 Asn Glu Phe Lys Leu Glu Leu Val Glu Lys Leu Phe Ala Glu Asp Thr  
 530 535 540  
 15 Glu Ala Lys Asn Pro Phe Ser Thr Gln Asp Thr Asp Leu Asp Leu Glu  
 545 550 555 560  
 Met Leu Ala Pro Tyr Ile Pro Met Asp Asp Asp Phe Gln Leu Arg Ser  
 565 570 575  
 Phe Asp Gln Leu Ser Pro Leu Glu Ser Ser Ser Ala Ser Pro Glu Ser  
 20 580 585 590  
 Ala Ser Pro Gln Ser Thr Val Thr Val Phe Gln Gln Thr Gln Ile Gln  
 595 600 605  
 Glu Pro Thr Ala Asn Ala Thr Thr Thr Thr Ala Thr Thr Asp Glu Leu  
 610 615 620  
 25 Lys Thr Val Thr Lys Asp Arg Met Glu Asp Ile Lys Ile Leu Ile Ala  
 625 630 635 640  
 Ser Pro Ser Pro Thr His Ile His Lys Glu Thr Thr Ser Ala Thr Ser  
 645 650 655  
 Ser Pro Tyr Arg Asp Thr Gln Ser Arg Thr Ala Ser Pro Asn Arg Ala  
 30 660 665 670  
 Gly Lys Gly Val Ile Glu Gln Thr Glu Lys Ser His Pro Arg Ser Pro  
 675 680 685  
 Asn Val Leu Ser Val Ala Leu Ser Gln Arg Thr Thr Val Pro Glu Glu  
 690 695 700  
 35 Glu Leu Asn Pro Lys Ile Leu Ala Leu Gln Asn Ala Gln Arg Lys Arg  
 705 710 715 720  
 Lys Met Glu His Asp Gly Ser Leu Phe Gln Ala Val Gly Ile Gly Thr

725 730 735  
 Leu Leu Gln Gln Pro Asp Asp His Ala Ala Thr Thr Ser Leu Ser Trp  
 740 745 750  
 Lys Arg Val Lys Gly Cys Lys Ser Ser Glu Gln Asn Gly Met Glu Gln  
 755 760 765  
 5 Lys Thr Ile Ile Leu Ile Pro Ser Asp Leu Ala Cys Arg Leu Leu Gly  
 770 775 780  
 Gln Ser Met Asp Glu Ser Gly Leu Pro Gln Leu Thr Ser Tyr Asp Cys  
 785 790 795 800  
 Glu Val Asn Ala Pro Ile Gln Gly Ser Arg Asn Leu Leu Gln Gly Glu  
 10 805 810 815  
 Glu Leu Leu Arg Ala Leu Asp Gln Val Asn  
 820 825

## (2) INFORMATION FOR SEQ ID NO:7:

## 15 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 810 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## 20 (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Ser Ser Glu Arg Arg Lys Glu Lys Ser Arg Asp Ala Ala Arg Ser  
 1 5 10 15  
 Arg Arg Thr Lys Glu Ser Glu Val Phe Tyr Glu Leu Ala His Gln Leu  
 25 20 25 30  
 Pro Leu Pro His Asn Val Ser Ser His Leu Asp Lys Ala Ser Val Met  
 35 40 45  
 Arg Leu Thr Ile Ser Tyr Leu Arg Val Arg Lys Leu Leu Asp Ala Gly  
 50 55 60  
 30 Gly Leu Asp Ser Glu Asp Glu Met Lys Ala Gln Met Asp Cys Phe Tyr  
 65 70 75 80  
 Leu Lys Ala Leu Asp Gly Phe Val Met Val Leu Thr Asp Asp Gly Asp  
 85 90 95  
 Met Val Tyr Ile Ser Asp Asn Val Asn Lys Tyr Met Gly Leu Thr Gln  
 35 100 105 110  
 Phe Glu Leu Ala Gly His Ser Val Phe Asp Phe Thr His Pro Cys Asp  
 115 120 125

His Glu Glu Met Arg Glu Met Leu Thr His Arg Asn Gly Pro Val Arg  
 130 135 140  
 Lys Gly Lys Glu Leu Asn Thr Gln Arg Ser Phe Phe Leu Arg Met Lys  
 145 150 155 160  
 Cys Thr Leu Thr Ser Arg Gly Arg Thr Met Asn Ile Lys Ser Ala Thr  
 5 165 170 175  
 Trp Lys Val Leu His Cys Thr Gly His Ile His Val Tyr Asp Thr Asn  
 180 185 190  
 Ser Asn Gln Pro Gln Cys Gly Tyr Lys Lys Pro Pro Met Thr Cys Leu  
 195 200 205  
 10 Val Leu Ile Cys Glu Pro Ile Pro His Pro Ser Asn Ile Glu Ile Pro  
 210 215 220  
 Leu Asp Ser Lys Thr Phe Leu Ser Arg His Ser Leu Asp Met Lys Phe  
 225 230 235 240  
 Ser Tyr Cys Asp Glu Arg Ile Thr Glu Leu Met Gly Tyr Glu Pro Glu  
 15 245 250 255  
 Glu Leu Leu Gly Arg Ser Ile Tyr Glu Tyr Tyr His Ala Leu Asp Ser  
 260 265 270  
 Asp His Leu Thr Lys Thr His His Asp Met Phe Thr Lys Gly Gln Val  
 275 280 285  
 20 Thr Thr Gly Gln Tyr Arg Met Leu Ala Lys Arg Gly Gly Tyr Val Trp  
 290 295 300  
 Val Glu Thr Gln Ala Thr Val Ile Tyr Asn Thr Lys Asn Ser Gln Pro  
 305 310 315 320  
 Gln Cys Ile Val Cys Val Asn Tyr Val Val Ser Gly Ile Ile Gln His  
 25 325 330 335  
 Asp Leu Ile Phe Ser Leu Gln Gln Thr Glu Ser Val Leu Lys Pro Val  
 340 345 350  
 Glu Ser Ser Asp Met Lys Met Thr Gln Leu Phe Thr Lys Val Glu Ser  
 355 360 365  
 30 Glu Asp Thr Ser Cys Leu Phe Asp Lys Leu Lys Lys Glu Pro Asp Ala  
 370 375 380  
 Leu Thr Leu Leu Ala Pro Ala Ala Gly Asp Thr Ile Ile Ser Leu Asp  
 385 390 395 400  
 Phe Gly Ser Asp Asp Thr Glu Thr Glu Asp Gln Gln Leu Glu Asp Val  
 35 405 410 415  
 Pro Leu Tyr Asn Asp Val Met Phe Pro Ser Ser Asn Glu Lys Leu Asn  
 420 425 430

Ile Asn Leu Ala Met Ser Pro Leu Pro Ser Ser Glu Thr Pro Lys Pro  
 435 440 445  
 Leu Arg Ser Ser Ala Asp Pro Ala Leu Asn Gln Glu Val Ala Leu Lys  
 450 455 460  
 Leu Glu Ser Ser Pro Glu Ser Leu Gly Leu Ser Phe Thr Met Pro Gln  
 5 465 470 475 480  
 Ile Gln Asp Gln Pro Ala Ser Pro Ser Asp Gly Ser Thr Arg Gln Ser  
 485 490 495  
 Ser Pro Glu Pro Asn Ser Pro Ser Glu Tyr Cys Phe Asp Val Asp Ser  
 500 505 510  
 10 Asp Met Val Asn Val Phe Lys Leu Glu Leu Val Glu Lys Leu Phe Ala  
 515 520 525  
 Glu Asp Thr Glu Ala Lys Asn Pro Phe Ser Thr Gln Asp Thr Asp Leu  
 530 535 540  
 Asp Leu Glu Met Leu Ala Pro Tyr Ile Pro Met Asp Asp Asp Phe Gln  
 15 545 550 555 560  
 Leu Arg Ser Phe Asp Gln Leu Ser Pro Leu Glu Ser Asn Ser Pro Ser  
 565 570 575  
 Pro Pro Ser Met Ser Thr Val Thr Gly Phe Gln Gln Thr Gln Leu Gln  
 580 585 590  
 20 Lys Pro Thr Ile Thr Ala Thr Ala Thr Thr Thr Ala Thr Thr Asp Glu  
 595 600 605  
 Ser Lys Thr Glu Thr Lys Asp Asn Lys Glu Asp Ile Lys Ile Leu Ile  
 610 615 620  
 Ala Ser Pro Ser Ser Thr Gln Val Pro Gln Glu Thr Thr Thr Ala Lys  
 25 625 630 635 640  
 Ala Ser Ala Tyr Ser Gly Thr His Ser Arg Thr Ala Ser Pro Asp Arg  
 645 650 655  
 Ala Gly Lys Arg Val Ile Glu Gln Thr Asp Lys Ala His Pro Arg Ser  
 660 665 670  
 30 Leu Asn Leu Ser Ala Thr Leu Asn Gln Arg Asn Thr Val Pro Glu Glu  
 675 680 685  
 Glu Leu Asn Pro Lys Thr Ile Ala Ser Gln Asn Ala Gln Arg Lys Arg  
 690 695 700  
 Lys Met Glu His Asp Gly Ser Leu Phe Gln Ala Ala Gly Ile Gly Thr  
 35 705 710 715 720  
 Leu Leu Gln Gln Pro Gly Asp Cys Ala Pro Thr Met Ser Leu Ser Trp  
 725 730 735



Lys Arg Val Lys Gly Phe Ile Ser Ser Glu Gln Asn Gly Thr Glu Gln  
740 745 750  
Lys Thr Ile Ile Leu Ile Pro Ser Asp Leu Ala Cys Arg Leu Leu Gly  
755 760 765  
Gln Ser Met Asp Val Ser Gly Leu Pro Gln Leu Thr Ser Tyr Asp Cys  
770 775 780  
Glu Val Asn Ala Pro Ile Gln Gly Ser Arg Asn Leu Leu Gln Gly Glu  
785 790 795 800  
Glu Leu Leu Arg Ala Leu Asp Gln Val Asn  
805 810

5

10

## WHAT IS CLAIMED IS:

1. An isolated protein comprising a endothelial PAS domain protein 1 (EPAS1) protein (SEQ ID NO: 4 or 5), or an EPAS1 protein domain thereof having at least 14 consecutive amino acids of SEQ ID NO: 4 or 5 and an EPAS1-specific activity.
- 5 2. An isolated protein according to claim 1, wherein said protein specifically binds at least one of a bHLH/PAS protein, a heat shock protein, or a nucleic acid consisting of SEQ ID NO:3.
3. A recombinant nucleic acid encoding a protein according to claim 1.
- 10 4. A cell comprising a nucleic acid according to claim 3.
5. A method of making an isolated EPAS1 protein, comprising steps: introducing a nucleic acid according to claim 3 into a host cell or cellular extract, incubating said host cell or extract under conditions whereby said nucleic acid is expressed as a transcript and said transcript is  
15 expressed as a translation product comprising said protein, and isolating said translation product.
6. An isolated EPAS1 protein made by the method of claim 5.
7. An isolated EPAS1 nucleic acid comprising SEQ ID NO: 1 or 2, or a fragment thereof  
20 having at least 24 consecutive bases of SEQ ID NO: 1 or 2 and sufficient to specifically hybridize with a nucleic acid having the sequence defined by the corresponding SEQ ID NO: 1 or 2 in the presence of human or murine genomic DNA, respectively.
8. An isolated EPAS1 nucleic acid according to claim 7, said nucleic acid comprising SEQ  
25 ID NO:1, or a fragment thereof having at least 24 consecutive bases of SEQ ID NO:1 and sufficient to specifically hybridize with a nucleic acid having the sequence defined by SEQ ID NO:1 in the presence of human genomic DNA.
9. An isolated EPAS1 nucleic acid according to claim 7, said nucleic acid comprising SEQ  
30 ID NO:2, or a fragment thereof having at least 24 consecutive bases of SEQ ID NO:2 and sufficient to specifically hybridize with a nucleic acid having the sequence defined by SEQ ID

NO:2 in the presence of murine genomic DNA.

10. A method of screening for an agent which modulates the binding of a EPAS1 protein to a binding target, said method comprising the steps of:

incubating a mixture comprising:

5 an isolated protein according to claim 1,

a binding target of said protein, and

a candidate agent;

under conditions whereby, but for the presence of said agent, said protein specifically binds said binding target at a reference affinity;

10 detecting the binding affinity of said protein to said binding target to determine an agent-biased affinity,

wherein a difference between the agent-biased affinity and the reference affinity indicates that said agent modulates the binding of said protein to said binding target.

15 11. A method according to claim 10, wherein said binding target is a one of a bHLH/PAS protein, a heat shock protein, or a nucleic acid consisting of SEQ ID NO:3.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/00813

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : 435/6, 7.1, 69.1, 252.3, 325; 530/350; 536/23.5, 24.31, 24.33

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 7.1, 69.1, 252.3, 325; 530/350; 536/23.5, 24.31, 24.33

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	TIAN et al. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 01 January 1997, Vol. 11, No. 1, pages 72-82, see entire document.	1-9 --- 10, 11



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

27 MARCH 1998

Date of mailing of the international search report

14 MAY 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ROBERT SCHWARTZMAN

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/00813

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C07H 21/04; C07K 14/00; C12N 1/21, 5/10, 15/12; C12P 21/00; C12Q 1/68; G01N 33/53

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

STN: Medline, Biosis, Embase, CAPlus, WPIDS, JAPIO, PATOSEP, PATOSWO  
APS

Search terms: EPAS1, endothelial, PAS domain

**THIS PAGE BLANK (USPTO)**